HIGH-THROUGHPUT DIAGNOSTIC ASSAY FOR THE HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)

Inventors: Joseph S. M. Peiris, Hong Kong (CN); Kwok Yung Yuen, Hong Kong (CN); Lit Man Poon, Hong Kong (CN); Yi Guan, Hong Kong (CN); Kwok Hung Chan, Hong Kong (CN); John M. Nichols, Hong Kong (CN); Frederick C. Leung, Hong Kong (CN)

Assignee: The University of Hong Kong, Hong Kong (CN)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 445 days.

Appl. No.: 10/807,807
Filed: Mar. 24, 2004
Prior Publication Data
US 2005/0181357 A1 Aug. 18, 2005

Related U.S. Application Data
Provisional application No. 60/457,031, filed on Mar. 24, 2003, provisional application No. 60/457,730, filed on Mar. 26, 2003, provisional application No. 60/459,931, filed on Apr. 2, 2003, provisional application No. 60/460,357, filed on Apr. 3, 2003, provisional application No. 60/461,265, filed on Apr. 8, 2003, provisional application No. 60/462,805, filed on Apr. 14, 2003, provisional application No. 60/464,886, filed on Apr. 23, 2003, provisional application No. 60/465,738, filed on Apr. 25, 2003, provisional application No. 60/470,935, filed on May 14, 2003.

Int. Cl.
C12Q 1/68 (2006.01)
C12Q 1/00 (2006.01)

U.S. Cl. 435/6, 435/4, 536/23.72, 536/24.32, 536/24.33

Field of Classification Search 435/5, 435/235.1, 91.2, 536/23.72, 24.32, 24.33

See application file for complete search history.

References Cited
U.S. PATENT DOCUMENTS
FOREIGN PATENT DOCUMENTS
WO WO 02/057302 7/2002

OTHER PUBLICATIONS

* cited by examiner
Primary Examiner—Bruce R. Campbell
Assistant Examiner—Louise Humphrey

Attorney, Agent, or Firm—Saliwanchik, Lloyd & Saliwanchik

ABSTRACT

The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.

5 Claims, 106 Drawing Sheets
a cag gac gct gta gct tca aat gaa tga tgg cct acg cag act gtt
Gln Asp Ala Val Ala Ser Lys Ile Leu Gly Leu Pro Thr Gln Thr Val
1 5 10 15
Gat tca tca cag ggt tct gaa tat gac tatt gtc ata ttc aca caa act
Asp Ser Ser Gln Gly Ser Glu Tyr Asp Tyr Val Ile Phe Thr Gln Thr
20 25 30
Act gaa aca gca cac tct tgg aat gtc aac cgc ttc aat gtt gct atc
Thr Glu Thr Ala His Ser Cys Asn Val Asn Arg Phe Asn Val Ala Ile
35 40 45
Aca agg gca aat ggt ctc tgg ata atg tct gat aga gat ctt
Thr Arg Ala Lys Ile Gly Ile Leu Cys Met Ser Asp Arg Asp Leu
50 55 60
tat gac aat ctc gaa ttt aca aat ctc gta gaa ata caa cgt cgc aat gtt
Tyr Asp Leu Gln Phe Thr Ser Leu Glu Ile Pro Arg Arg Asn Val
65 70 75 80
gct aca tta cca gca gaa aat gta act gga ctt ttt aag gac tgt agt
Ala Thr Leu Gln Ala Asn Val Thr Gly Leu Phe Lys Asp Cys Ser
85 90 95
aag atc att act ggt ctt cat cct aca cag gca cct aca cac ctc agc
Lys Ile Ile Thr Gly Leu His Pro Thr Gln Ala Pro Thr His Leu Ser
100 105 110
gtt gat ata aac ctc aag act gaa gga tta tgt gtt gac ata cca ggc
Val Asp Ile Lys Phe Lys Thr Glu Gly Leu Cys Val Asp Ile Pro Gly
115 120 125
ata cca aag gac atg acc tac cgt aga ctc atc tct atg gtt gtt tct
Ile Pro Lys Asp Met Thr Tyr Arg Leu Ile Ser Met Met Gly Phe
130 135 140
aaa atg aat tac cca gca aat ggt tac cct aat atg ttt atc acc cgc
Lys Met Asn Tyr Gln Val Asn Gly Tyr Pro Asn Met Phe Ile Thr Arg
145 150 155 160
gaa gaa gct att cgt cac gtt cgt ggc tgt att ggc ttt gat gta gag
Glu Ala Ile Arg His Val Arg Ala Trp Ile Gly Phe Asp Val Glu
165 170 175
ggc tgt cat gca act aga gat gct gtt ggt act aac cta cct ctc cag
Gly Cys His Ala Thr Arg Asp Ala Val Gly Thr Asn Leu Pro Leu Gln
180 185 190
cta gga ttt tct aca ggt aat ggt ctc gta gct gta cct cgc act gtt tat
Leu Gly Phe Ser Thr Gly Val Asn Leu Val Ala Val Pro Thr Gly Tyr
195 200 205
gtt gac act gaa aat aac cta
Val Asp Thr Glu Asn Asn Leu
210 215
t  aaa  tgt  agt  aga  ata  cct  gcg  cgt  gcg  gcg  gta  gag  tgt  ttt  gat
   Lys  Cys  Ser  Arg  Ile  Ile  Pro  Ala  Arg  Ala  Arg  Ala  Glu  Cys  Phe  Asp
  1    5     10    15

aaa  ttc  aaa  gta  aat  tca  aca  cta  gaa  caq  tat  gtt  ttc  tgc  act  gta
   Lys  Phe  Lys  Val  Asn  Ser  Thr  Leu  Glu  Gln  Tyr  Val  Phe  Cys  Thr  Val
 20    25    30

aat  gca  ttg  cca  gaa  aca  act  gct  gac  att  gta  gtc  ttt  gat  gaa  atc
   Asn  Ala  Leu  Pro  Glu  Thr  Thr  Ala  Asp  Ile  Val  Val  Phe  Asp  Glu  Ile
 35    40    45

tct  atg  gct  act  aat  tat  gac  ttg  aat  gtt  gtc  aat  gct  aga  ctt  cgt
   Ser  Met  Ala  Thr  Asn  Tyr  Asn  Leu  Ser  Val  Val  Arg  Ala  Arg  Leu  Arg
 50    55    60

gca  aaa  cac  tac  gtc  tat  att  ggc  gat  cct  gct  caa  tta  cca  gcc  ccc
   Ala  Lys  His  Tyr  Val  Tyr  Ile  Gly  Asp  Pro  Ala  Gln  Leu  Pro  Ala  Pro
 65    70    75   80

cgc  aca  ttg  ctc  act  aaa  ggc  aca  cta  gaa  cca  gaa  tat  ttt  aat  tca
   Arg  Thr  Leu  Leu  Thr  Lys  Gly  Thr  Leu  Pro  Glu  Tyr  Phe  Asn  Ser
 85   90    95

gtg  tgc  aga  ctt  atg  aaa  aca  ata  ggt  cca  gac  atg  ttc  ctt  gga  act
   Val  Cys  Arg  Leu  Met  Lys  Thr  Ile  Gly  Pro  Met  Phe  Leu  Gly  Thr
100  105    110

tgt  cgc  cgt  tgt  cct  gct  gaa  att  gtt  gac  act  gtg  aat  gct  tta  gtt
   Cys  Arg  Arg  Cys  Pro  Ala  Glu  Ile  Val  Asp  Thr  Val  Ser  Ala  Leu  Val
115  120    125

tat  gac  aat  aag  cta  aaa  gca  cac  aag  gag  tca  gct  caa  tgc  ttc
   Tyr  Asp  Asn  Lys  Leu  Lys  Ala  His  Lys  Glu  Asp  Thr  Val  Ser  Ala  Gln  Cys  Phe
130  135    140

aaa  atg  ttc  tac  aaa  ggt  gtt  att  aca  cat  gat  gtt  tca  tct  gca  atc
   Lys  Met  Phe  Tyr  Lys  Gly  Val  Ile  His  Asp  Ser  Val  Ser  Ser  Ala  Ile
145  150    155    160

aac  aga  cct  caa  ata  ggc  gtt  gta  aga  gaa  ttt  ctt  aca  cgc  aat  cct
   Asn  Arg  Pro  Gln  Ile  Gly  Val  Arg  Glu  Leu  Thr  Arg  Asn  Pro
165    170    175

gct  tgg  aga  aaa  gct  gtt  ttt  atc  tca  cct  tat  aat  tca  cag  aac  gct
   Ala  Trp  Arg  Lys  Ala  Val  Phe  Ile  Ser  Pro  Tyr  Asn  Ser  Gln  Asn  Ala
180   185    190

gta  gct  tca  aaa  atc  tta  gga  ttg  cct  acg  cag  act  gtt  gat  tca  tca
   Val  Ala  Ser  Lys  Ile  Leu  Gly  Leu  Pro  Thr  Glu  Thr  Val  Asp  Ser  Ser
195   200    205

cag  ggt  tct  gaa  tat  gac  tat  gtc  ata  ttc  aca  cca  act  act  gaa  aca
   Gln  Gly  Ser  Glu  Tyr  Asp  Tyr  Val  Ile  Phe  Thr  Glu  Thr  Thr  Glu  Thr
210  215    220

FIG. 8
FIG. 8 Con’t
FIG. 9
FIG. 10 Con’t
FIG. 10 Con't
FIG. 10 Con't
FIG. 10 Con't
FIG. 10 Con't
FIG. 10 Con't
FIG. 11
FIG. 11 Con’t
1681 - GTTGCCATCATTTTTGCGCATTCTTCTCTCTAAGTGGACTTATTTGACATATAAG - 1740
   - VAILLASSAFSAVADIFTIDIK
   - LPSFWHLSSLVLPQVLILLR
   - CHFFIFLCFLYKCLHYKKE

1741 - AGCTCGTACTACCGAGTCTCTTCCAAGGCAGTATGCTTCTGCTGGTACTAAT
   - SDLYKFSKTVESCNGKVT
   - VLTSLSKPLLSPAVTIKLHP
   - S*LQVFQNHCC*VLRL*LSYQ

1801 - AAGGGGAAACCCGCGTAAAAGAGGTCGACATCAAACGAAAGCACAGGTGGATCGTTATCC
   - KGPKVGBAWNIGQQRVRVLTTP
   - RESP*KVGLTLDNRDFQHF'H
   - GKAARKRCLETWETHFNTT

1861 - CTGTGTTGTTTTCCCCTCAAGGGCAAGGTCTGGTCTATTACGATACATTTTTGCGGACACATT
   - LCFSPSQAAGVIRSIARL
   - CVLFPFHRLLVLSDLQFRLRHL
   - VWFSTGTGCWCYQINFCAH

1921 - GATCGACAGCCACGCTCAATTTCTGACATCATGCTGACAGAGACAGGTGACAGCTGCTCACG
   - DAAANHSIPDLQRAAATILDG
   - MQQTQFLICKEQOLSPYLMV
   - CSDKPLNS*FARKSSCHHT*WY

1981 - ATCTCTGAGACTTATCTATGCTATGCTTGTGGACAGCGATGGTTATTACGCTAGCTGCTACC
   - ISEQSLRLVTDAMVYTSDLTLT
   - FLNSHYVLSTPWFILQCTCSP
   - F*TVITSCRRHGLYFRPAHQ

2041 - AACAGTGTGTTATTAGTGCTATGATACGACTGGTGCTTATTACGACAGATCTCAGTGTTG
   - NSVIIMAYVTGGLVQQTSW
   - TVSLLILWHM*LVLVLYNRLLSG
   - QCYHIIDCNWWSCCTTFDSVV

2101 - TTGTGCTAACTCTTTGCGACACGCGCTATGCTTTGAGAAATCAGCGCTATCTGCTTG
   - LSNNLLGTVKCLRPIFIWIE
   - CLIFWALLLLKNSGGLSQLGLRL
   - V*SFGHYC*KTQAYL*MDG

2161 - GCGGAAACTTATGTGACAGAGTTGATATTCTCAAGAGATGCTTGGGAGATTCTCCTAAATTCTC
   - AKLSAGVEFRRKDAWEILFKL
   - RNLVLQVEFLNLFSRMLGRFSNF
   - ETCRS*IOLSCGCGLDSDQISH

2221 - ATCCAGGTGTGTTTGGAGATCTGCTGACAGGGCGACATCCAGACAGCTGCTG
   - ITGVFVDVTKGQIQVASSN
   - LQVFLLTSVRKRYLRLQITSR
   - YRCF*HRQGSNTGCFCR*HQG

2281 - GATTTGTTAAAAACGGCTCTATGGAGGTGTTGAAACAGACAAGCTGGAAATGGCATTGATCA
   - DCKVCFIDVNVKALEMCMJDQ
   - IV*NASMLMLIRHSKCALIK
   - LCMKLH*CC*QGRTRNVHSS

2341 - GTCTAGCTTGCGGCAGAAGGTCGACTGTACACTTAGGGAAGTGCTTCGGCTACTACGA
   - VTIGAKGLRSLNLGEVFIAQ
   - SLSLTAQSCDHDST*VKSSSLK
   - HRYWRKVVAITQOLR*SLHRSK

2401 - AGCCAGGACCTTACCGTCTAGTGATACGGCAGAAGGACGCTGCAACTTCATCGCTCA
   - SKGLYRQCIROGKEQLQMLM
   - ARDFCTVSVYVARSSCNYSC
   - QTGLPLPSVYWTQGAAATTHAS

2461 - CTATAGCAGCCAAAACAGAAGACTCTTCTGGAGTGATCTCAGACACAGATCTACCTAC
   - LKAPEFTFLEGDSHDRVTLP
   - LRHQQK*PFLKVLHVMTQYLP
   - GTKRSNLSR*FTHSTLYL

FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con’t
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con’t
FIG. 11 Con't
FIG. 11 Con't

13441 - CAGGCAC7AGTAGCTGAGTGTCCCTAGGATTTATTTACAGCAAGAAAAAGTCTAG - 13500
- Q A L V L M S S T G L L I F T T K R V L
- R H Y * C R L Q G F + Y L Q R K R K C W
- G T S T D V V Y R A F D I Y N E K S A G
13501 - GTTTGCGAAGATCTTTCTTAAAGACTATTTGCTGCTGCTCAGGAAAGATAGAGGAGGCA - 13560
- V Q L S S * K L I A V A S R R R M R K A
- F C K V P K N * L L S L P G E G * G R Q
- F A K F L K T N C R Q E K D E E G N
13561 - ATTTATACACCTTTACATTTGATAGTAAAGGATCAGCTATACATGTCTCTACATACATGAG - 13620
- I Y * T L T L * L R G I L L C L T T N M K
- F I R L L L C S * E A Y Y V * L P T * R
- L L D S Y F V V K R H T M S N Y Q H E E
13621 - AGACTTATTTATACTTTGATAGTAAAGGATCAGCTATACATGTCTCTACATACATGAG - 13680
- H L F I T W L K I V Q R L L S M T F S S
- D Y L * L G * R L S S G C C P + L F Q V
- T I Y N L V K D C P A V A V H D F F K F
13681 - TTAGTGATAGTGAGCAGATGTACACATATATACCGCTAGCTAATTAATCTGCTTTTAAGT - 13740
- L E * M V T W Y H I Y H V S V * L N T Q
- * S R W * H G T T Y I T S A S N * I H N
- R V D G D M V P H I S R Q R L T K Y T M
13741 - TGGCTGATTATTTAGCTTATAGCTCAGTATTTGATAGGAGGATAGATATAGCTATACATAAG - 13800
- W L I * S M L Y V I L M R V I I * K
- G F S L C S T S F * * G * L * Y I K R
- A D L S V Y A L R H F D E G N C D T L K E
13801 - AAATACGTCGATACATATAGCTATACATGATATATATCTGCTTTTAAGT - 13860
- K Y S S H T T I A V M M I I S I R I G M
- N T R H I Q L L * * L F Q * E G L V *
- I L V T Y N C D D D D Y F N K K D W Y D
13861 - ACTTCGATAGTAGCTTTTCGACTCTAGCTGTTATAGGCTATAGCTATACATGCTGCTGAGCC - 13920
- T S * R I L S T Y A Y M L T * V S V Y A
- L R R E S * H L T R I C * L R * A C T P
- T V E N P D I L R V Y A N L G E R V Q
13921 - AATCATATTTAAAGACTCTGACATTCTGCTTATAGGCTATAGCTATACATGCTGCTGAGCC - 13980
- H L Y * R L Y N H S A M L C V M Q A L * A
- I I I K D C T I L R C Y A * C R H C R R
- S L L K T V Q F C D A M R D A G I V G V Y
13981 - TACCTGATACATTGATTATTACAGAATCTGATTTGATAGGAGGATAGATATAGCTATACATAAG - 14040
- Y * H * I I I R I L M G T G T I S V I S Y
- T D I R * S G S * W E L V R F R * F R T
- L T L D N Q D L N G N W Y D F G D F V Q
14041 - AAGTACGATACATTGATTATTACAGAATCTGATTTGATAGGAGGATAGATATAGCTATACATAAG - 14100
- K * H Q A A E F L L W I H I T H C * C P
- S S T R L R S S Y C G F I L I I A D A H
- V A P G C G V P I V D S Y Y S L L M P I
14101 - TCTACTACTTTAGCTGACAGCTTGCTATGTATATGATATAGCTATACATGCTGCTGACAAC - 14160
- S S L * L G H W L L L S P I W M L I S Q N
- P H F D + G I G C * V P Y G C * S R K T
- L T L R A L A E H S M A D A D L A R P
14161 - CACCTTATTTAAATTTGGAACCGACCGATACCTTTTTTGCTGCTGCTATATGAGGAGGAGAGGAGGATCTTTTGATGAT - 14220
- H L L S G I C * N M I L R K R D F V S S
- T Y * V G F A E I * F Y G R E T L S L R
- L I K W D L L K Y D T E E R L C L F D
14221 - ACCGTATTTTTTTTAAAATTTGAGGACCGACCGATACCTTTTTTGCTGCTGCTATATGAGGAGGAGGAGGATCTTTTGATGAT - 14280
- T V I L N I G T R H T P I V I T V V W
- P L F S I L G P D I P S Q L Y * L F C *
- R Y F K Y W D Q T Y N P N C I N C L D D

FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
15961 - TGGATGCTTACCCACTTACAACCAATACCTAATCATGGAGTATGCTGATGCTTCTCACTTTG
- L M T L H L Q N I L I R S T L M S F T C
- * C L P T Y K T S * S G V C * C L S L V
- D A Y P L T K H P N Q E Y A D V F H L Y
16020 - AATTTACAAATACATTAGAAAGTTACATGATGAGCTTACTGGGCCACATGTTGAGCATGTATT
- I N Y T L E S Y M S L L A T C W T C I
- F T I H * K V T * A Y W P H V G H V F
- L Q Y I R K L H D E L T G H M L D M Y S
16080 - CCGTATGCTAATACAACTGAGCTGACATTGCTGCGAGCTGCTATGTGCAATGTGACAGTA
- P C * V L M I T H G T G N L S F M R L
- R N A N * * H L T V L G T * V L * G Y
- V M L T N D S R Y W E P E F Y E A M
16140 - TGTGACCACTGACATGACATGCTTGGAGTCAACATTCTCCCAATGTTGCCAGAATGTGCCATAG
- C T H I Q S C R L * V L V Y C A I H R
- V H T Y S L A G C R C L C I V Q F T D
- Y T P H T V L Q A V G A C V L C N S Q T
16200 - CTTGACTTCCGTCGGGTGCGTATTACCCATATTGAGGAGCCTACCTCAATGGTCATGTGC
- L H F V A P V V L G D H S V A S A A M
- F T S L R C L Y * E T I P M L Q V L L *
- S L R C G A C I R R P F L C K C C Y D
16260 - ACCACACATCCTTCACACACATCACCACATCACCACATTGATGGTTTCTGATGACATG
- T M S F Q H T N * C C L I P F M A M
- P C H F N I T Q I S V V C * S L C L Q C
- H V I S T S H K V L V S V N P Y V C N A
16320 - CCCCAGTTGTTGAGTGATGTCAGTGTGAGCGAATCCATCTGAGGAGGATGATGACATTATT
- P Q V V M S L M * H N C I * E V * A I I
- P R L * C H * C D T T V S R R Y E L L L
- P G C D V T D V T Q L Y L G G M S Y Y C
16380 - GCAAGTCACATAGGGCTCCCATATTGTACATTGCTGATGCTAAATGTCAGGGTTGGTCTCTCC
- A S H I S L P L V F H Y V L M V R F L V
- Q V T * A S H * F S I M C * W S G F W F
- K S H K P P I S F P L C A N Q V F G L
16440 - TATACAAACAAACATGATGGCTAGCAGCAATGCTAATGCTGCACTCAGACCTGAATGAGTC
- Y T K T H V * A V T M S L T S M R * Q H
- I Q K H M C R Q * Q C H * L Q C D S N M
- Y K N T C V G S D N V T D F N A I A T C
16500 - GTGATTGAGTGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGTGATGGT

FIG. 11 Con’t
FIG. 11 Con't
FIG. 11 Con't
21001 - ATGTGACAAAGAGAATGACTCTAAAGAGAAGGGTTTTTTCACCTTATCTGTGATTTTATA
- M*QKRMFLKGGPSLICVDL
- CDSKRE*LRRVFHLSTWYK
- VTKEKNSKEGFYFTLGCIFK

21061 - AGCAAAACTAGCCCTGGGTGGTTCTATAGCTGTAAGATACAGAGCATCTGTGGGATG
- SKN*PWWVL*RQSIILGM
- AKTSPGWFSCKDNRAFLEC
- QKLALGGSIAVKITEHSWNA

21121 - CTTGACTCTTAACAGCTTTATTGATGCCACCTATATCTCTGCTGAACCTTTTGAAATAC
- LTFTLSWAIHSHGGQLLLQ*M
- *PLQAYGPFFLMVDSFCYKCK
- DLYKLGMGHFSWWTATFVTNVA

21181 - ATGCTACACTCATCGAGTCTTAAGATTTTTAACATGGGCTCAATCTCTTGCAACGCGAGAAC
- MHHHRKHF*LGLTLILASRRN
- CIIGISIFNWGLSLWQAEGT
- ASSSEAFLIGANYLGPKPEQ

21241 - AAATGCTAGTGCGCTATACATTCATATCGCTATTATCTCAGACTTGATTTCTCTGCAAG
- KLIMAPCMLTFTSGGQTILS
- N*WLYHAC*LHFLLEEHHKSYPM
- IGDYTMHANYIFWRNTPNIPQ

21301 - AGGTGCTCTCGCTACTATCTATAGGCTCAATTTCTGCTGAGACCTTTATTAGAGGACAG
- SCLPIHLT*ANFLN*EELE
- VVFLFSTL*HEQISS*IHRNC
- LSSYSLFDMSKFPKLRGTAA

21361 - CTGTATATCTCTTTAAGAGGACTAAATCAATATGATTTATCTCTTCCTCGAAAAG
- L*CLRRKSMIFILFWKK
- CNVSGESNQ*YDLFSSGKR
- VMSLKEQNINDMIYESLLEK

21421 - GTAGGCTTTACATTAGAGAAAACACAGATGTTGCTCGATATCTCCGATAAACA
- VGLSLETTLWFQVIFFLT
- *AYH*RKQOQSCGFKYSCPQ
- RLIIRERNVRVVSDDILVNN

21491 - ACTAAACGAACTATTTATTATTTCTCACTCTACACTTGATTTGACCTTTG
- TKRRTCLFSYVYLSSLVVSVL
- LNEHVVYFLISYSH*NW**P *
- *TNMFIFLLFLTLTSGSDLD

21541 - ACCGGTGACCACTTTTTTATGATGCTCGCTCTCAACTCTACACACTCACTCTACCTCA
- TGAAPLMKFLLMLTLINLH
- PVHHF*CSSS*LSHTYFIY
- RCTTFDDVQAPYNTQTHTSSM

21601 - TGGAGGGGTTCATCTCAGTTAAGATTTTTAGATGGCAGACCTCTTTATTTAATCTCAG
- *GGFLKMDQTLFILIR
- EGGLLS*NFIHRHSLFNSG
- RGVYYPDEIFRSRDTLYLTD

21661 - ATTGTATCTCTTCATTATTTATTATTCTAATGTCTACAGGTTATCTACTTTATATTGTG
- IYFFHFILMLQQGFLILLIIRL
- FISSILFP*CYRYSVYVSYSVWV
- LFLFPYFNSVNTGFHTINHTF

21721 - GCAGGCTGCTGATCCTTTAAGAGATGGATTTTTATTTTTTGCTGCCCACAGGAAAATCAATAC
- ATLSYLLRMVFFILLPQRMQ
- QPCHTF*GWYLFCCHREIKC
- NEVIFPKDIGFYAATEKSNV

21781 - TTGCTCCTCGCTGAGGTTATTTTTTGGGTATCTGATGACACAAACAGTACATGCTGATTTATT
- LSYYVGVFLVLP*TTSSR*L
- CWPWLGFWFWFYHEQOQVTVGVYDYY
- VRGWVFSGSTMNNKSQSIVII

FIG. 11 Cont’
FIG. 11 Con't
22681 - TACGSCAGGACAAACTGCTGTTATATGTGATATTATATAATTAAATGGCACAGTATTTCA - 22740
  - * RQDKLVLLILIIINICQMS
  - SARTNWCYC*L*L*IAR*FH
  - AQPQTGTVIADYNKLPDDDFM

22741 - TGGTTTGTGCTCCTGCTGGGATATCCTGACATTGCTGCTACTGTTACACCTGTGAAATATA - 22800
  - WVSLLGILGTLMMLQLLVII
  - GLCPCELEY*EH*CFCYFNW*L*
  - GCVLAWNTRNIDATSTGTGNYN

22801 - ATATTAATAATATAGATCTATTCCTAGCTGTCAGACATTGGCCTTGTTGAGAGACACATC - 22860
  - ILINIGILDMASLGFLRETYL
  - L*I*VSTWQR*AL*ERHII*
  - YKRYRLHSGKLRLPERFDISN

22861 - ATATGCCTTCTTCCTCCTGATTGGCAAACATTGGCCACACATGTTAATGTTTATGGC - 22920
  - MCPLAMLAPHLLEIVIG
  - CAFLL*WQTLHPTCS*LILPA
  - VPFFSDGPDKPCTPPALNCYWP

22921 - CATTAAAATGTTATAGTGTGTTATATACACACTACTGGCATGCTGCTACACCTACGGCTT - 22980
  - H*MIMVFTPLLALATLNLTEL
  - IKL*LWHFLHYYWHWLPTLQSC
  - LNDYGEYTTTGIQGYQFPRRVV

22981 - TACCACTTCTCTTCTGATTGCAACTTAATATGCGCCAGGCTTTCGTTTGGAAATAATTCCCA - 23040
  - *YFLNFM*MHRRPFDQYNP
  - SFF*TFKCTGTHGLWTKIHH
  - VLSFELLNAPATVCGPKLST

23041 - CGTACCTATTATAGACACACTGCTGATTTATATATATGATTAGCACAATCTGTGATTTG - 23100
  - LTLRLRTSVEISILIIMDSLVVLV
  - *PY*EPVCQF*F*WTHWYWLC
  - DLIKNQCVNFNFNGLTTGTV

23101 - TGGTAACTCTCTCCCCATTCACATTCAACTCTAAAATGGCAGTACCGTACATTTATGCTGCTT - 23160
  - *C*LLQLRDFENHFHNILAVMFL
  - LTPSSKRFQPQFQFGRDVBD

23161 - ATATGCCTGATTCCCTCTATCCTACCAATCCACAAATTTATGACATCTCTTTACCTGCT - 23220
  - ISLIPFEILKHLKY*TFHLA
  - FHH*RFRSRS*NIT*NIRHFTLL
  - FTDSVRDPKTEILDIPCS

23221 - CTTTGGGCGTGATGATGATATACACTGGACAAATCTGTGCTCTGTGCATGCTGCT - 23280
  - LLLGV*V*LHLEQMLHLKLLLF
  - FWGCKCMNITYWKNKCFI*SCCS
  - EGGVSVPITPTGTNASSESEAVL

23281 - TATATACAGATGTTACCTGACACTGATATGTTTCTACAGCATCTGAGATAGATACACTCAC - 23340
  - YIKMLMLMFLQQFMQINS
  - IYSCILHCYFYSNNSCRCSTHT
  - YQDVNCNTDVSSTAIDADQLTP

23341 - CAGCTTGGCGGCTATATTACTGTTGAAACATGTATTTCAGCAGCTCAACGGCTGTCTTTA - 23400
  - QLGAYLLEMYLSRLQKAVL
  - SLLAHIFYWKQCIPDDSSRLSY
  - AWRRIYSTGNNVFQTOAGCLL

23401 - TACGACCTGAGCATTGGTACACTTATATGATGCTGCTACATTTATGACATTGGACATATT - 23460
  - *ELSMSTLLMSSMATSFLLEELAF
  - RSR*ACRHFL*VRSYSWWSWHL
  - GAHEVDTSYECDIPIGAGIC

23461 - GTGACTATTACCATGACGTTTTTCTTATTACTGACTGACGTCCAAATACATTGTGCTGCTT - 23520
  - VLVTTIQFLYVYVVLAKNLLWLL
  - C*LPYSPFFIT*Y*PKIYCGCL
  - ASYHTVSLRLRSTSQKSIYAVY

FIG. 11 Con’t
24361 - GTTGTCTAAAAATGTATCCCTTTCCGGCAGCTTTGATAAAGTCGAGGCAGGAGGTACAAATTCACA - 24420
  - V C * M I S F R D L I K S R R R Y K L T
  - C A K * Y P F A T * * S R G G G T N * Q
  - V L N D I L S R L D K V E A E V Q I D R
24421 - TGGTTATATACGGAGGACTTCTAAACCTGGTTCGAAACCATACACAACACTCTAACTCAGGG - 24480
  - G * L Q A D F K A F K P M * H N N * S G
  - V N Y R Q T S K P S N L C N T T T N Q G
  - L I T G R L Q S L Q T Y V T Q Q L I R A
24481 - GTGCTGAAAACACATGGCGCTTCTTCTGCTAACTGCTGTAAGTATGTGCAGTGATTGTT - 24540
  - L L K S G L L L L L L L L K L C L S V F L
  - C * N Q G F C * S C C Y * N V * V C S W
  - A E I R A S A N L A A T K M S E C V L
24541 - GCAAATCCAAAAGAATGATCTTTTGTTGAAAGGTCTCACCACACTTATAATTGGCTATCC - 24600
  - D N Q K E L T F V E R A T T L C F S H K
  - Q S K R V D F C G K G Y H L M S F P Q A
24601 - CAGCCCCGGATGGTGGTGGTCCCTCTACATGCAGTGGCGTGTACGTCCAGAGAGAG - 24660
  - P R V L L S Y S M R S R M C H P R G T
  - S P A W C C L P T C H V C A I P G E E L
  - A P H G V V F L H V T Y V E S Q E R N F
24661 - TCCACCAACGCCGGACGAAATTCGTAACTAAGCGGCAAAGCTACATCTCCCTGTGAGGTTT - 24720
  - S P Q R Q Q F V M K A K H T S L V K V F
  - H H A S N L S * R Q S I L P S * R C F
  - T T A P A I C H E G K A Y F P R E G V F
24721 - TTGTGTATATAGGCTCTCTTGGTATAATTACACAGAGAATCCTCTTCTGTTCACAATATA - 24780
  - L C M L A D L L H L R G T S F L H K *
  - C V * W H F L V Y Y T E E L L L F S T T N N
  - F K N T S W F I T Q R N F F S P Q I I
24781 - TTACTACAGACCAAACTTATCTGCTGACTAGCTGATCTACTCTCCCTGTGAGGTTT - 24840
  - L L Q T I H L S O E I V M S L L A S L T
  - Y Y R Q Y I C L R K L * C R Y W H H * Q
  - T T D N T F V S G N C D V V I G I I N N
24841 - ACAGAGTTTATGAGCCTCAGTCTGCAAGCATGTGACTCTTCAAAGAAGAGAGCTGGCAAGT - 24900
  - T Q F M I L C N D S L T H S S K K S W T S
  - T V Y D P L Q O P E L D S F K E E L D K Y
24901 - ACTTAAAAATACATACATACACAGAATGCTTCTTGGGCGACATTTTACAGGGATTACGT - 24960
  - T S K I I H I T R C * S W R H F R H * R F
  - F K N T S P D V D L G D I S G I N A S
24961 - CTGTCGTCACACATTTACAAAAGAATAATGGCAGCCCTCAATAGGGTCTCAAAATTAAATG - 25020
  - L S S T F K K K L T A S M R S L K I * M
  - C R Q H S K R N * F P Q * G R * K F K *
  - V V N I Q K E I D R L N E V A K N L N E
25020 - AATCCACTCATGCACTCCATAGAAATGCGGAAAATAATTAGGCAAGCATATATAATATATGCTTGGT - 25080
  - N H S L T F K N W E N M S N I L N G L
  - I T H * P S R I G K I * A T Y * M A L V
  - S L D L D L Q E L G K Y E Q Y I K W F W Y
25080 - AGTTTGTTGCATGCTGGCATATGTGGCATGACCTATGCTGTGGATGTTCAATGCTTCTGTTT - 25140
  - M F G S A S L L D * L P S S W L O S C F
  - C L A R H C W T N C L R H G N Y N L A L
  - V W L G F I A G L I A I V W M T I L L C
25140 - GTGCGATGCTGTTGTGTGGAGCTGCTGTGGATGTTCAATGCACGTGTTGTGTGGATGTT - 25200
  - V A * L V V A V A S R V H A L V V L L A A
  - L H D * L L Q L P Q G C M L L L W F F L L Q
  - C M T S C C S C L K G A C S C G S C C K

FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Cont
FIG. 11 Con't
FIG. 11 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't

26881 - ACCGGATTCACACAGTGATAGAGACAGACACTTTTCATGAAACAGCTTTGCAACACGATTTATC - 26940
- TGFNSVDFRALFIKHPVFVNTF -
- PDSNV*TEHFSLSLSTLSTRSS -
- RIQRCRQSTFHALCQHVHQ

26941 - AACGCTCAATAGTGATTCTCCTGACTCTTCTGTAACACACCTTCCCAACAGATTCACTTCC - 27000
- KLCLESILVTLNFPNSIFS -
- SNVILTFLP*PSTSTQTVSSP -
- AQSMSFSLNHELPLKQYLIQ

27001 - AAAGGTTAACCTTGATAGTGCTCCCCCTTATTAACGGGAAGACATACTGTTGTGACCGA - 27060
- KGTYTFNWCTFPAKDIVCSCQ -
- KVTPLIGAPPFFKRKLTFVAS -
- RLHSLVLHPLLSERHCLPV -

27061 - TAAACGGAGGAGCAATGGCGACGAGATATGTCTTGGTGTCCTTAACTCTCTAAGACGAGCTAGCC - 27120
- *TRHCAVLFFVLNL*EHSEA -
- KPGDNAQYCSLLSLISKSMRPH -
- NOETMRSIVLCP*SLRA*GH -

27121 - AATTACACAGACTTTGTTGCGACGACATATCTACATTTGCTGACAGATATCAACCGGCCTCTC - 27180
- IYTDWCAADDSSICEAINGRL -
- FTQTGGVTIAFVVKLSSTGV -
- LHRVLCRRHLH*SYQASR -

27181 - GAGTGCTCGAATTCCCTGAGTCAGTGCTGAGACAACACTCGAGATATGCCTCTCAATGTGATCT - 27240
- ECFFETVTLVWNLLRLRGLKCV -
- SASSSPFFLRRTTSSSEVSTVSC -
- VLRVHRS*EQPPQRP*VLCHV -

27241 - TGATACCCCTCAGAAGGATTACCTGGTCTGCTGAGGCAGCTAGATCGGATCTTCC - 27300
- *ITFGBKGYFFWCCLKRHE*LQ -
- ESSPSRKVTSGALRGMSSCS -
- NFLQLERRLLCLVP*EA*VVAA -

27301 - CTGCTCTCCTGACCGATTATACACTGACGGATTAAATCTCCTTGATGCAGTGAAGATCTCTTCC - 27360
- LLLATYTTLTVTKLALSDEDF -
- CSSLPRH*R*SPPLL*AMKTS -
- APCHVYTDGKVPCFERRLRLH -

27361 - ACCCTAGTGATGCACTGCAACTTGTGCGACCGACTGATATGTGACTTGATCAATGCACATTTT - 27420
- T*VE*SQCLASDSDLINAHF -
- PKLSDRNFAPAPAIVT*SMHIS -
- LSVIATLRQ*LLLLDCQCTFR -

27421 - GAGTGCTCTTCTAACAGCATGATAGCTGATTTACCACTAATCTTGATGTCTTTCGAG - 27480
- ECLVONINAEFYTILDVDINS -
- SCLTLTTNMSKHTQSLMSEAE -
- VPTCQHHSEQLSILHNP*CYLRQ -

27481 - AACCTGTATTGCTCTGGAGGATGGCTGGCAAAAACACTCGTAATGGAATATTTTGAGAATCTC - 27540
- NLYLTTTLDDDVKNCTCNKEFKENL -
- TCI*PLTMSKTPVMRNLRI -
- PVFDP*RQCKHL*EIESP -

27541 - CCAAGCCTACCTGGAGAATTCCTACCTCCTGACGTGTTGTGCAACTCCATACATCAAGAT - 27600
- PSEILEFKNSCTKFRLPNFNKD -
- QASLSRNSTPLSASHISIK -
- KHP*EIQSLHL*VSPQSIQ*R -

27601 - AGGCGCTGATTTTCCAAACAGTATGACAGCGACCTACACTGTAAGTCTTCC - 27660
- RPEFFNSSAQSQRQPLRSLL -
- GLSFSTVVPKRLDNHEVCC -
- A*VFQCRCKD*TTEKSVV -

27661 - TACAGACCCAAGGTTACCAATATCTGCTCTATAAGACACATGTGTCATTGTGACCGA - 27720
- YKTTSYICHNNNDTVGEOQV*S -
- TRPPVTYAIIMTTLLVSRSEV -
- QDHQLHMP**HCW*AGLKY -
FIG. 12 Con't
FIG. 12 Con't
N-gene primers (nucleotide position 29247-29410)
  150# (5’-gactgatgaagctaggcctt-3’)
  200# (5’-cttgtgtgtgctcattgagtg-3’)

S-gene primers (nucleotide position 24751-25049)
  131# (5’-cacagaggaaccttttttt-3’)
  132# (5’-tcccaattcttgagaaggtcaatgag-3’)

FIG. 13
ATGTCGTAATGGACCCCAATCAAACACGTAGTGGCCCCGCATTACATTTGGTGA
CCACAGATCTGACTGACTATACCAGATGGAGGCAGGACATGGGGCAGGCAAACAG
CAGCTGGCCAGACGCTATGCTACTAGCTACCGATGGTCAGTCTCATCCCTTGGGAC
GGGATCAAGAGCTAGGAGGACATGTTCAATATCAATACAGGCTAGTGGTGGTCTAG
AAAATGAAGAGCTACGCCCCGATGTTACTCTTAATTACATAGAAGTGGGCTTA
CACATCTCAGAAGAACACATGGTCGCTACGTAGTCGTCGGTAGTCTAAGATACCTCT
GGCAGCAGTTAGGGAAATCTCTCTGCTAGAATGGCTAGGGAGGATGTGGGAAACTGCCCT
GGATATTGTGCTAGCAGATTTGAACCCGTCTAGAGCAGCAAATTTGCTGACTAAAG
CAAACACCAAGCGAATTTGCGGAGAACAGGGATAACTAGCAAGAACACTGATTAACAA
CTTTGGCCGAAAATTCAGAATGGTCTGTCCAATTGGATCTGTCAATTTGGGAGAGTGC
ATTGGCATGGAGTCACATTTCCGGGATCATGGCTGACTTTACATGGGAGGCACTCAA
GATAAAAGATCCAAATATCAAGACACGCTATCTGCTGAACAGCAACATTTGAGCAG
TACAAACACTTCCACCAACAGGGCTAAAGAGGAAAAGGAAGAAAGACTGATGAGACT
CAGCCTTTGCGCGAGACAAAAGAAGAGGAGGCCCAGCTGAGCTCTCTCTTCTCCGGGCTAG
ATGGATGTATTTCTCAGACAACTTTCAAATCTCATGAGTTGAGCTTCTGCTGATTCAC
CAGGCAATAA

FIG. 14A
FIG. 14B
FIG. 15A
FIG. 15A Con’t
FIG. 15B
FIG. 16
FIG. 19
- Primers for a 225-bp fragment of the region of N-gene that showed no homology to other coronavirus:

  SRS251: 5’-GCAGTCAAGCCTTTCTCG-3’ (SEQ ID NO:2480)
  SRS252: 5’-GCCTCAGCAGGATTTC-3’ (SEQ ID NO:2481)

- Primers for 181-bp fragment of the region of 1b-gene:

  coro3: 5’-TACACACCTCAGCGTTG-3’ (SEQ ID NO:3)
  coro4: 5’-CACGAACTGACGAAT-3’ (SEQ ID NO:4)

- Primers for a 745-bp fragment from pig β-actin gene:

  Actin-F: 5’-TGAGACCTTCAACAGCC-3’ (SEQ ID NO:2482)
  Actin-R: 5’-ATCTGCTGGAAGGTGGAC-3’(SEQ ID NO:2483)

**FIG. 20**
FIG. 21A

FIG. 21B
FIG. 22A

FIG. 22B
FIG. 23
<table>
<thead>
<tr>
<th>Probe</th>
<th>Region</th>
<th>SEQ ID NO</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ib</td>
<td>18057 – 18222</td>
<td>2484</td>
<td>gatataaaaattcaagactgaagggattatgttgtgacacataaaccgcatacaaagggacat</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>gacctacagtacactctctctatgatgggttcaaatgaatccaaagtaatggaatggtaacct</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ctaatatgtttatcacccgcgaagaagctattgcgtacgttcggtg</td>
</tr>
<tr>
<td>S</td>
<td>21920 – 22107</td>
<td>2485</td>
<td>catgaggtacacagacacatactatggatattgcaatttacttgctgtttccagaaagcaggttaa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ttacctaatctaccttaaaactactaagccactgtagtagttgttttttaaaagggctatcaacctagttag</td>
</tr>
<tr>
<td>M</td>
<td>26867 – 26996</td>
<td>2486</td>
<td>gcttgacattaggagccaaagagagctacagtggctacatactacgaacgcctttctt</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>attacaaattaggagcgtcgcagctgtaggcactgattcaggttttgctgcatacaacc</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>gctacccgtat</td>
</tr>
<tr>
<td>N</td>
<td>28658 – 28883</td>
<td>2487</td>
<td>gcagtcagctctttctcgtctcctcatacagttgcgcgttaattcaagaattcactcctgaggccagttagggaatttctctgctgaatggctggagtctgcggacgcagagccccctgcagttgctagacagattg</td>
</tr>
</tbody>
</table>

**FIG. 25**
1
HIGH-THROUGHPUT DIAGNOSTIC ASSAY
FOR THE HUMAN VIRUS CAUSING SEVERE
ACUTE RESPIRATORY SYNDROME (SARS)

This application claims priority benefit to U.S. provisional
application No. 60/457,031, filed Mar. 24, 2003; U.S. provi-
sional application No. 60/457,730, filed Mar. 26, 2003; U.S.
provisional application No. 60/459,031, filed Apr. 2, 2003;
U.S. provisional application No. 60/460,357, filed Apr. 3,
2003; U.S. provisional application No. 60/461,265, filed Apr.
8, 2003; U.S. provisional application No. 60/462,805, filed
Apr. 14, 2003; U.S. provisional application No. 60/464,886
filed Apr. 23, 2003, U.S. provisional application No. 60/465,
738, filed Apr. 25, 2003; and U.S. provisional application No.
60/470,935, filed May 14, 2003, each of which is incorpo-
rated herein by reference in its entirety.

The instant application contains a lengthy Sequence listing
which is being concurrently submitted via triplicate CD-R in
lieu of a printed paper copy, and is hereby incorporated by
reference in its entirety. Said CD-R, recorded on Mar. 22,
2004, are labeled “CRF,” “Copy 1” and “Copy 2”, respec-
tively, and each contains only identical 1.6 MB file
(V9661077.APP).

1. INTRODUCTION

The present invention relates to a high-throughput diagno-
stic assay for the virus causing Severe Acute Respiratory
Syndrome (SARS) in humans (“SARS virus”). In particular,
the invention relates to a high-throughput reverse transcription-
PCR diagnostic test for SARS associated coronavirus (SARS-
CoV). The present assay is a rapid, reliable assay which
may be used for diagnosis and monitoring the spread of
SARS. The present method eliminates false negative results
and provides increased sensitivity for the assay. The invention
further relates to nucleotide sequences and portions thereof,
useful for the diagnosis of SARS. The invention further
relates to nucleotide sequences and portions thereof, useful
for assessing genetic diversity of SARS. The nucleotide
sequences of the present invention comprise the (Nucleo-
capsid) N-gene and the S-gene sequences of the SARS virus.
The invention relates to a diagnostic kit that comprises molar
acid molecules for the detection of the N-gene or S-gene of
SARS virus. The invention also relates to the deduced amino
acid sequences of the N-gene and S-gene products of the SARS
virus. The invention further relates to the use of the N-gene
and S-gene products in diagnostic methods. The invention
further encompasses diagnostic assays and kits comprising antibodies generated against the
N-gene or S-gene product.

2. BACKGROUND OF THE INVENTION

Recently, there has been an outbreak of atypical pneu-
monia in Guangdong province in mainland China. Between
November 2002 and March 2003, there were 792 reported
cases with 31 fatalities (WHO. Severe Acute Respiratory
Patients with SARS show various clinical symptoms, includ-
ing fever (of 38 degrees Celsius or above for over 24 hours),
malaise, chills, headache and body ache. Chest X-rays show
changes compatible with pneumonia. Other symptoms
include coughing, shortness of breath or difficulty in breath-
ing. By 3 May 2003, a cumulative total number of 1621 cases
and 179 deaths had been occurred in Hong Kong, which
corresponded to 26% and 41% of the global reported cases
(6234) and deaths (435) respectively. As the disease is highly
contagious and spreads in daily-life activities, it is important
to develop a rapid and reliable diagnosis test to monitor and
control the disease. In response to this crisis, the Hospital
Authority in Hong Kong has increased the surveillance on
patients with severe atypical pneumonia. In the course of this
investigation, a number of clusters of health care workers
with the disease were identified. In addition, there were clus-
ters of pneumonia incidents among persons in close contact
with those infected. The disease was unusual in its severity
and its progression in spite of the antibiotic treatment typical
for the bacterial pathogens that are known to be commonly
associated with atypical pneumonia. The present inventors
were one of the groups involved in the investigation of these
patients. All tests for identifying commonly recognized
viruses and bacteria were negative in these patients.
Furthermore, diagnostic tests for the detection of other genes in
the SARS virus, such as the 1b-gene are not useful to accurately
diagnose SARS. The disease was given the acronym Severe
Acute Respiratory Syndrome (“SARS”). This virus mutates
and changes rapidly and hence the diagnostic of SARS was
extremely difficult until the isolation of particular regions of
the virus, the N-gene and S-gene, of the SARS virus from the
SARS patients by the present inventors as disclosed herein.
Namely, the present invention discloses a diagnostic assay
using particular regions in the genome of the virus for rapid,
accurate, reliable and specific identification of the SARS
virus. The invention is useful in both clinical and scientific
research applications. Furthermore, the present invention
provides a high-throughput assay which can be used as a
sensitive method for diagnosis and monitoring the spread of
the SARS.

3. SUMMARY OF INVENTION

The present invention is based upon the inventors’ identi-
fication of a specific region of the SARS virus, specifically,
the 3’region of the SARS viral genome, and in particular, the
(nucleocapsid) N-gene of the SARS virus that may be used
diagnostic assay to detect SARS. In particular, the N-gene
is useful for the diagnosis of SARS because the N-gene has
the most abundant copy number during viral infection com-
pared to any other gene in the SARS virus, especially when
the cells are lysed. Thus, the nucleic acid sequences of the
N-gene of the SARS virus are particularly useful in a rapid
and reliable diagnostic assay for the SARS virus. Further-
more, the present method eliminates false negative results and
increases the sensitivity of the assay.

The SARS virus was isolated from patients suffering from
SARS in the recent outbreak of severe atypical pneumonia in
China. The isolated virus is an enveloped, single-stranded
DNA virus of positive polarity which belongs to the order,
Nidovirales, of the family, Coronaviridae. The SARS virus
is a very large RNA virus consisting of approximately 29,742
nucleotides. The complete genomic sequence of the SARS
virus was deposited in Genbank. NCBI with Accession No:
AY278491 (SEQ ID NO:15), which is incorporated by refer-
ence. The isolated SARS virus was deposited with China
Center for Type Culture Collection (CCTCC) on Apr. 2, 2003
and recorded an accession number, CCTCC-V200303, as
described in Section 7, infra, which is incorporated by refer-
ence. Also, the entire genome sequence of the SARS virus,
CCTCC-V200303, and characterization thereof are disclosed
in a United States patent application with Attorney Docket
No. V9661.0069 filed concurrently herewith on Mar. 24,
2004, which is incorporated by reference in its entirety. The
virus mutates and changes rapidly and hence making the
diagnostic of SARS very difficult. The present inventors have
designed a diagnostic assay for detecting the presence of N-gene nucleic acid sequence or protein to rapidly, accurately, and specifically identify the hSARS virus. Furthermore, the present inventors have designed a diagnostic assay for detecting the presence of S-gene nucleic acid sequence or protein to determine the genetic diversity of the hSARS virus. Accordingly, the invention relates to methods of detecting nucleotide sequences of the N-gene and S-gene of the hSARS virus.

The present invention provides a rapid, reliable assay for the detection of hSARS virus. In preferred embodiments, the detection of hSARS virus includes the use of the nucleic acid molecules of the present invention in a polymerase chain reaction, Reverse transcription-Polymerase Chain Reaction (RT-PCR), Southern analysis, Northern analysis, or other nucleic acid hybridization for the detection of hSARS nucleic acids. In one embodiment, the invention provides methods for detecting the presence, activity or expression of the hSARS virus in the invention in a biological material, such as cells, nasopharyngeal aspirate, sputum, blood, saliva, urine, stool and so forth. In preferred embodiments, the biological material is nasopharyngeal aspirate or stool. The increased or decreased activity or expression of the hSARS virus in a sample relative to a control sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the hSARS virus. In a specific embodiment, the detecting agents are the nucleic acid molecules of the present invention.

The present invention also relates to a method for identifying a subject infected with the hSARS virus, said method comprising obtaining total RNA from a biological sample obtained from the subject; reverse transcribing the total RNA to obtain cDNA; and subjecting the cDNA to PCR assay using a set of primers derived from a nucleotide sequence of the hSARS. In preferred embodiments, the primers are derived from the (nucleosidic) N-gene. In most preferred embodiments, the primers comprise the nucleotide sequences of SEQ ID NOS:2475 and/or 2476 or SEQ ID NOS:2480 and/or 2481. In anotherpreferred embodiments, the primers are derived from the (spike) S-gene. In more preferred embodiments, the primers comprise the nucleotide sequences of SEQ ID NOS:2477 and/or 2478.

The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471, or 2473, or a complement thereof, or at least a portion of the nucleotide sequence thereof. In the most preferred embodiment, the primers comprise the nucleic acid sequence of SEQ ID NOS:2475 and/or 2476 or SEQ ID NOS:2480 and/or 2481 for the detection of N-gene. In another more preferred embodiment, the primers comprise the nucleic acid sequence of SEQ ID NO:2477 and/or 2478 for the detection of S-gene. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for hybridization to hSARS nucleic acid, including, but not limited to, as PCR primers, Reverse Transcription primers, probes for Southern analysis or nucleic acid hybridization analysis for the detection of hSARS nucleic acids, e.g., consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471, 2473, 2475, 2476, 2477, 2478, 2480 or 2481, or a complement thereof, or a portion thereof. In a preferred embodiment, primers that amplify fragments comprising (nucleotide position 18057 to 18222 or portions thereof of SEQ ID NO:15) 1b gene; (nucleotide position 21920-22107, or portions thereof of SEQ ID NO:15) M-gene; and (nucleotide position 28658-28883, or portions thereof of SEQ ID NO:15) N-gene may be used for probe synthesis for detection of hSARS nucleic acids. In a specific embodiment, the invention provides a diagnostic kit comprising nucleic acid molecules which are suitable for use to detect the N-gene of hSARS. In a specific embodiment, the N-gene comprises nucleic acid sequence of SEQ ID NO:2471. In specific embodiments, the nucleic acid molecules comprise nucleic acid sequence of SEQ ID NOS:2475 and/or 2476 or SEQ ID NOS:2480 and/or 2481. In preferred embodiments, the diagnostic kit further comprises a control for amplification of 1b gene. In specific embodiments, the primers used for amplifying 1 b gene are SEQ ID NOS:3 and/or 4. In another specific embodiment, the diagnostic kit further comprises an internal control using pig β-actin gene. In specific embodiments, the primers used for amplifying β-actin gene are SEQ ID NOS:2482 and/or 2483.

In a specific embodiment, the invention provides a diagnostic kit comprising nucleic acid molecules which are suitable for use to detect the S-gene of hSARS. In a specific embodiment, the S-gene comprises nucleic acid sequence of SEQ ID NO:2473. In a specific embodiment, the nucleic acid molecules comprise nucleic acid sequence of SEQ ID NOS:2477 and/or 2478. The invention further encompasses chimeric or recombiant viruses encoded in whole or in part by said nucleotide sequences.

In another specific embodiment, the invention provides nucleic acid molecules comprising a nucleotide sequence of SEQ ID NO:1, 11, 13, 2471, and/or 2473. In a specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, or a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:11, or a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:13, or a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:15, or a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 16000, 17000, 18000, 19000, 20000, 21000, 22000, 23000, 24000, 25000, 26000, 27000, 28000, 29000, 30000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide
sequence of SEQ ID NO:2471, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2471, or a complement thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2473, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2473, or a complement thereof. Furthermore, in another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 11, 13, 15, 2471, or 2473, or a complement thereof. In one embodiment, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid of the invention. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. In another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by the sequence of SEQ ID NO:1, 13, 2471, or 2473. In other embodiments, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2471, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45,
NO:2472, or 2474. The invention further provides antibodies that specifically bind polypeptides of the invention encoded by a nucleic acid comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:15, and/or any hSARS epitope, having one or more biological activities of a polypeptide of the invention. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab)\_, fragments, disulfide-linked Fv's, intrabodies and fragments containing either a V\_L or V\_H domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In another embodiment, the invention provides vaccine preparations, comprising the hSARS virus, including recombinant and chimeric forms of said virus, or protein subunits of the virus. In a specific embodiment, the vaccine preparations of the present invention comprise live but attenuated hSARS virus with or without adjuvants. In another specific embodiment, the vaccine preparations of the invention comprise an inactivated or killed hSARS virus. Such attenuated or inactivated viruses may be prepared by a series of passages of the virus through the host cells or by preparing recombinant or chimeric forms of virus. Accordingly, the present invention further provides methods of preparing recombinant or chimeric forms of hSARS. In another specific invention, the vaccine preparations of the present invention comprise a nucleic acid or fragment of the hSARS virus, e.g., the virus having accession no. CCTCC-V200303, or nucleic acid molecules having the sequence of SEQ ID NO:1, 11, 13, 15, 2471 or 2473, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides isolated from or produced from nucleic acid of hSARS virus, for example, of deposit accession no. CCTCC-V200303. In a specific embodiment, the vaccine preparations comprise a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 11, 13, 2471 or 2473, or a fragment thereof. In a specific embodiment, the vaccine preparations comprise polypeptides of the invention as shown in FIGS. 11 (SEQ ID NO:18-239, 241-736 and 738-1107) and 12 (SEQ ID NO:1109-1589, 1591-1964 AND 1966-2470) or encoded by the nucleotide sequence of SEQ ID NO:15, or a fragment thereof. In a specific embodiment, the vaccine preparations comprise polypeptides comprising amino acid sequence of SEQ ID NO:2472 or 2474. Furthermore, the present invention provides methods for treating, ameliorating, managing or preventing SARS by administering the vaccine preparations or antibodies of the present invention alone or in combination with adjuvants, or other pharmaceutically acceptable excipients.

In another aspect, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. In a specific embodiment, the anti-viral agent of the invention is an antibody that immunospecifically binds hSARS virus or any hSARS epitope. In preferred embodiments, such antibodies neutralize the hSARS virus. In a specific embodiment, the anti-viral agent of the invention binds a fragment, variant, homolog of N-gene or S-gene of hSARS virus. In a specific embodiment, the anti-viral agent of the invention binds a fragment, variant, homolog of a polypeptide comprising the amino acid sequence of SEQ ID NO:2472 or 2474. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the present invention or nucleic acid molecule of the invention. The invention also provides kits containing a pharmaceutical composition of the present invention.

3.1 Definitions

The term “an antibody or an antibody fragment that immunospecifically binds a polypeptide of the invention” as used herein refers to an antibody or a fragment thereof that immunospecifically binds to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471 2473, or the polypeptides shown in FIGS. 11 and 12, or a fragment thereof, and does not non-specifically bind to other polypeptides. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention may cross-react with other antigens. Preferably, an antibody or a fragment thereof that immunospecifically binds to a polypeptide of the invention does not cross-react with other antigens. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention, can be identified by, for example, immunoassays or other techniques known to those skilled in the art.

An “isolated” or “purified” peptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of a polypeptide/protein in which the polypeptide/protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, a polypeptide/protein that is substantially free of cellular material includes preparations of the polypeptide/protein having less than about 30%, 20%, 10%, 5%, 2.5%, or 1%, (by dry weight) of contaminating protein. When the polypeptide/protein is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When polypeptide/protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the polypeptide/protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than polypeptide/protein fragment of interest. In a preferred embodiment of the present invention, polypeptides/proteins are isolated or purified.

An “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment of the invention, nucleic acid molecules encoding polypeptides/proteins of the invention are isolated or purified. The term “isolated” nucleic acid molecule does not include a nucleic acid that is a member of a library that has not been purified away from other library clones containing other nucleic acid molecules.

The term “portion” or “fragment” as used herein refers to a fragment of a nucleic acid molecule containing at least about 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, or more contiguous nucleic acids in length of the relevant nucleic acid molecule and having at
least one functional feature of the nucleic acid molecule (or the encoded protein has one functional feature of the protein encoded by the nucleic acid molecule); or a fragment of a protein or a polypeptide containing at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,100, 4,200, 4,300, 4,350, 4,360, 4,370, 4,380 amino acid residues in length of the relevant protein or polypeptide and having at least one functional feature of the protein or polypeptide.

The term “3′ region of the hSARS viral genome” refers to from about nucleotide position 18,000 to 29742 of SEQ ID NO:15.

The term “having a biological activity of the protein” or “having biological activities of the polypeptides of the invention” refers to the characteristics of the polypeptides or proteins having a common biological activity similar or identical structural domain and/or having sufficient amino acid identity to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 16, 240, 737, 1108, 1590, 1965, 2471 or 2473. Such common biological activities of the polypeptides of the invention include antigenicity and immunogenicity.

The term “under stringent condition” refers to hybridization and washing conditions under which nucleotide sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to each other remain hybridized to each other. Such hybridization conditions are described in, for example but not limited to, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6; Basic Methods in Molecular Biology, Elsevier Science Publishing Co., Inc., N.Y. (1986), pp. 75-78, and 84-87; and Molecular Cloning, Cold Spring Harbor Laboratory, N.Y. (1982), pp. 387-389, and are well known to those skilled in the art. A preferred, non-limiting example of stringent hybridization conditions is hybridization in 6x sodium chloride/sodium citrate (SSC), 0.5% SDS at about 68°C followed by one or more washes in 2x SSC, 0.5% SDS at room temperature. Another preferred, non-limiting example of stringent hybridization conditions is hybridization in 6x SSC at about 45°C followed by one or more washes in 0.2x SSC, 0.1% SDS at about 50-65°C.

The term “variant” as used herein refers either to a naturally occurring genetic mutant of hSARS or a recombinantly prepared variation of hSARS each of which contain one or more mutations in its genome compared to the hSARS of CCTCC-V200303. The term “variant” may also refers either to a naturally occurring variation of a given peptide or a recombinantly prepared variation of a given peptide or protein in which one or more amino acid residues have been modified by amino acid substitution, addition, or deletion.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a partial DNA sequence (SEQ ID NO:1) and its deduced amino acid sequence (SEQ ID NO:2) obtained from the SARS virus that has 57% homology to the RNA-dependent RNA polymerase protein of known Coronaviruses.

FIG. 2 shows an electron micrograph of the novel hSARS virus that has similar morphological characteristics of coronaviruses.

FIG. 3 shows an immunofluorescent staining for IgG antibodies that are specifically bound to the FrHuK-4 cells infected with the novel human respiratory virus of Coronaviridae.

FIG. 4 shows an electron micrograph of ultra-centrifuged deposit of hSARS virus that was grown in the cell culture and negatively stained with 3% potassium phospho-tungstate at pH 7.0.

FIG. 5A shows a thin-section electron micrograph of lung biopsy of a patient with SARS; and FIG. 5B shows a thin section electron micrograph of hSARS-infected cells.

FIG. 6 shows the result of phylogenetic analysis for the partial protein sequence (215 amino acids; SEQ ID NO:2) of the hSARS virus (GenBank accession number AY268070). The phylogenetic tree is constructed by the neighbor-joining method. The horizontal-line distance represents the number of sites at which the two sequences compared are different. Bootstrap values are deducted from 500 replicates.

FIG. 7A shows an amplification plot of fluorescence intensity over the PCR cycle in a real-time quantitative PCR assay that can detect a hSARS virus in samples quantitatively. The copy numbers of input plasmid DNA in the reactions are indicated. The X-axis denotes the cycle number of a quantitative PCR assay and the Y-axis denotes the fluorescence intensity (FI) over the background. FIG. 7B shows the result of a melting curve analysis of PCR products from clinical samples.Signals from positive (+ve) samples, negative (-ve) samples and water control (water) are indicated. The X-axis denotes the temperature (°C) and the Y-axis denotes the fluorescence intensity (FI) over the background.

FIG. 8 shows another partial DNA sequence (SEQ ID NO:11) and its deduced amino acid sequence (SEQ ID NO:12) obtained from the SARS virus.

FIG. 9 shows yet another partial DNA sequence (SEQ ID NO:13) and its deduced amino acid sequence (SEQ ID NO:14) obtained from the SARS virus.

FIG. 10 shows the entire genomic DNA sequence (SEQ ID NO:15) of the SARS virus.

FIG. 11 shows the deduced amino acid sequences obtained from SEQ ID NO:15 in three frames (see SEQ ID NO:16, 240 and 737). An asterisk (*) indicates a stop codon which marks the end of a peptide. The first-frame amino acid sequences: SEQ ID NO:17-239; the second-frame amino acid sequences: SEQ ID NO:241-736; and the third-frame amino acid sequences: SEQ ID NO:738-1107.

FIG. 12 shows the deduced amino acid sequences obtained from the complement of SEQ ID NO:15 in three frames (see SEQ ID NO:1108, 1590 and 1965). An asterisk (*) indicates a stop codon which marks the end of a peptide. The first-frame amino acid sequences: SEQ ID NO:1109-1590; the second-frame amino acid sequences: SEQ ID NO:1591-1964; and the third-frame amino acid sequences: SEQ ID NO:1965-2470.

FIG. 13 shows the N-gene primer sequences (which amplifies nucleotides at position 29247-29410 of SEQ ID NO:2471). 150# (SEQ ID NO:2475); 200# (SEQ ID NO:2476); and S-gene primer sequences (which amplifies nucleotides at position 24751 to 25049 of SEQ ID NO:2473). 131# (SEQ ID NO:2477); 132# (SEQ ID NO:2478).

FIG. 14A shows the nucleic acid sequence of the N-gene (SEQ ID NO:2471). FIG. 14B shows the amino acid sequence of the N-gene (SEQ ID NO:2472).

FIG. 15A shows the nucleic acid sequence of the S-gene (SEQ ID NO:2473). FIG. 15B shows the amino acid sequence of the S-gene (SEQ ID NO:2474).

FIG. 16 shows the genome organization and transcription strategy of SARS-CoV 1H-39. Genomic and mRNA transcripts are capped (black circles), carry leader sequences (vertical lines) at 5′proximal and are polyadenylated (A15). Arrows point the position of the intergenic sequence, 5′CTAAACGACAG-3′ (SEQ ID NO:2479). After release of
the positive-sense genomic RNA in the cytoplasm of host cell, the viral RNA-dependent RNA polymerase, encoded from ORF 1a and 1b, is synthesized. It carries out transcription of a full-length complementary (negative-sense) RNA, from which new genomic RNA, an overlapping set of subgenomic mRNA transcripts, and leader RNA are synthesized. Note that all transcripts are preceded with common 5' leader sequences and common 3' ends. ORF1a and 1b—RNA-dependent RNA polymerase; S—major peplomer glycoprotein; M—membrane glycoprotein; N—nucleoprotein; X1, X2, X3—putative protein. PCR. FIG. 17 shows a construct map of pSARS-CoV-ORF 1b-N. PCR products amplified from ORF1b (1b) and N gene of SARS-CoV were co-ligated into a cloning vector pCR2.1 TOPO (Invitrogen). The nucleotide (nt) numbers corresponds to the positions in the sequence of HK-39 strain SARS-CoV (AY278491). Shadowed areas indicate the amplicons by the primers used in diagnostic test (i.e., SEQ ID NO:2480 and 2481).

FIG. 18 shows a photo of an agarose gel after electrophoresis of total RNA extracted from SARS patients using SV Total RNA isolation system. The extracted RNA was then subjected to a reverse-transcription polymerase chain reaction (RT-PCR) assay for the detection of coronavirus in the patients.

FIG. 19 shows the effect of potential inhibitors in Reverse Transcription Polymerase Chain Reaction (RT-PCR). To remove potential inhibitors, total RNA eluted from SV96 Binding Plate was precipitated with 95% ethanol and 3 M sodium acetate and resuspended in 12 μl of nuclease-free water. RT-PCR was performed with actin-F (SEQ ID NO:2482) and actin-R (SEQ ID NO:2483) primers. Numbers indicated were the number of pig kidney epithelial (PK-15) cells added in the sample as an internal control. There was no DNA fragment amplified with untreated RNA samples.

FIG. 20 shows the primers used for amplifying various genes. SRS251 (SEQ ID NO:2480) and SRS252 (SEQ ID NO:2481) amplified a 225 base pair fragment from the region of N-gene that showed no homology to other coronavirus, coro3 (SEQ ID NO:3) and coro4 (SEQ ID NO:4) amplified RNA-dependent RNA polymerase (1b gene) as a control. Actin-F (SEQ ID NO:2482) and actin-R (SEQ ID NO:2483) amplified a 745 base pair fragment from P-actin gene as internal control for PCR assays.

FIG. 21A shows Amplification plot of fluorescence Intensity against the number of PCR cycles. Blank lines show the dynamic range of N-gene specific PCR with serially diluted plasmid construct from 10^0 to 10^6 copies. NPA samples from non-SARS patients, including patients suffering from adenovirus (n=5), respiratory syncytial virus (n=5), human metapneumovirus (n=5), influenza A virus (n=5), or influenza B virus (n=5) infection, are shown in gray lines. Lines with triangles denotes the SARS-CoV positive NPA samples; NTC represents no template control; X-axis indicates the cycle number of quantitative PCR performed, while Y-axis represents the fluorescence intensity (FAM-400) over background signal (Delta Rn). Inlet shows the melting curve analysis of the PCR products. Signals from positive (+ve) and negative (−ve) samples and no template control are indicated. X-axis indicates the temperature (°C C.), while Y-axis represents the fluorescence intensity (Delta Rn). FIG. 21B shows comparison of dynamic ranges of N-gene and 1b-gene specific PCRs. Dynamic ranges of both N-gene and 1b-gene PCR were obtained with same plasmid construct in which 1:1 ratio of corresponding amplicons were subcloned. Serially diluted plasmid with copy number ranged from 10^0 to 10^6 copies was used as template in both PCRs. Lines with triangles denotes N-gene specific PCR while the gray lines indicates 1b-gene specific PCR. Inlet shows Ct values standard deviation in triplicate set of experiment of both PCRs with different copy numbers of template used. NTC represents no template control; X-axis indicated the cycle number of quantitative PCR performed, while Y-axis represents fluorescence intensity.

FIGS. 22A and 22B show an amplification curve and a melting curve, respectively, of real-time quantitative PCR specific to 1b (using the primers having SEQ ID NO:3 and 4) and N gene (using the primers having SEQ ID NO:2480 and 2481) of SARS-CoV. FIG. 22A: Amplification plot of fluorescence intensity against the number of PCR cycles. One (1) μl of cDNA from a NPA, tracheal dispersion and lung biopsy of patients with clinical symptoms were used as template in each PCR. Fifty (50) cycles of PCR were performed to achieve the saturation phase of the reaction. X-axis indicates the cycle number of quantitative PCR performed, while y-axis represents the fluorescence intensity (FAM-490) over background signal. Horizontal gray line indicates the calculated threshold value by maximum curvature approach, and the baseline cycle Ct was calculated automatically. Inlet shows half-maximal fluorescence value (1/2 max) and Ct of both PCR with cDNA from various tissue isolated from a key patient (patient A indicated in New Engl. J. Med. 348:1963-76) in three different time points. NPA—nasopataryngeal aspirate, TW—tracheal wash, LW—lung wash. FIG. 22B: Melting curves of PCR products. Melting curve analysis was carried out after 10-minute further-extension step of the reaction. The temperature was raised from 56°C to 94°C by 0.5°C each, while each set-point temperature had been held for 7 seconds for data collection and analysis. Melting temperature of 1b- and N-gene specific PCR products was 80.5°C and 85.5°C respectively. X-axis indicates the temperature in degree Celsius while Y-axis represents the fluorescence intensity (FAM-490) over background signal. One (1) μl of water was used as no template control in the reaction.

FIG. 23 shows the diagnostic result of 48 clinical samples using the primers having SEQ ID NO:2480 and 2481, respectively, with β-actin PCR as an internal control. Upper bands in each row showed a 745 bp DNA fragment amplified with actin-F and actin-R, while lower bands were the amplimers by primers specific for N-gene of SARS coronavirus (225 bp). –ve control (water) and +ve control (cDNA from SARS coronavirus infected vero cell) of the assay were indicated. Five (5) μl of PCR products of both reactions were mixed and loaded into the sample well in a 2% agarose gel. M=1 kb plus molecular marker (Invitrogen).

FIG. 24 shows Northern Blot analysis of SARS-CoV total RNA. Total RNA of SARS-CoV was extracted from SARS-CoV infected Vero E6 cell. RNA was separated in a 1% denaturing gel containing 6.29% formaldehyde. Afterwards RNA was transferred to positively charged nylon membrane and hybridized with digoxigenin-labelled PCR fragments specific to 1b, S, M and N genes, respectively. Lane 1-1b: lane 2-2S; lane 3-M; lane 4-N. Vertical bar showed the molecular size reference. Arrows indicates the transcripts hybridized with N probe. Signals were analyzed by chemiluminescence.

FIG. 25 shows the DNA probes used in Northern blot analysis. The probes for 1b gene (nt 18057-18222; SEQ ID NO:2484), S gene (nt 21920-22107; SEQ ID NO:2485), M
gene (nt 25867-26996; SEQ ID NO:2486), and N gene (nt 28658-28883; SEQ ID NO:2487) are shown.

5. DETAILED DESCRIPTION OF THE INVENTION

The present inventors developed a rapid, high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV), 3' region of the hSARS virus genome including the Nucleocapsid gene (N-gene) represents a sensitive molecular marker which can be used in addition to 19 gene to increase the sensitivity of the test. An internal control using PK-15 cells may be employed to ensure the integrity of RNA during its extraction process and cDNA synthesis, thus eliminating false negative results.

In mouse hepatitis virus (MHV), a typical member of the genus Coronavirus, both genomic RNA and mRNA transcripts are capped and with common 5' ends and common leader sequences on their 5' ends. With this unique transcription strategy, the copy numbers of different viral genes during proliferation of virus in its host are different (FIG. 19). N gene that encodes for the nucleocapsid has the most abundant copy number during virus replication as all transcripts can carry nucleotide sequence from N gene, although they are not all in-frame for translation for this gene product. The present inventors have discovered a diagnostic assay that is based on the 3' region, including the N-gene, of the viral genome to provide a more sensitive assay than the rest of the viral genome. Accordingly, in preferred embodiments, nucleic acid molecules that may be used for a diagnostic assay comprise nucleic acid sequence of nucleotide position 18000 to 29742 of SEQ ID NO:15, or portions thereof. The portions may comprise 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200 of nucleotides having nucleic acid sequence from nucleotide position 18000 to 29742 of SEQ ID NO:15. In other preferred embodiments, nucleic acid molecules that may be used for a diagnostic assay comprising nucleic acid sequence of nucleotide position 28658 to 28883 or 29247-29410 of SEQ ID NO:15.

Nasopharyngeal aspirate (NPA) and stool samples were obtained from SARS suspected patients with major clinical symptoms and significant history of close contact with infected patients. Total RNA was extracted from the subject samples, together with PK-15 cell as an internal control. Samples were analyzed by the reverse-transcription-PCR assay. Northern blot analysis was performed to show different subgenomic transcripts of the virus. Real-time quantitative PCR was employed to compare the sensitivity of two loci used in this diagnostic assay. In specific embodiments, PCR inhibitor was removed with ethanol precipitation after RNA extraction process.

In preferred embodiments, the present invention provides a method for detecting the presence or absence of nucleic acid of the N-gene in a biological sample. The method involves obtaining a biological sample from various sources and contacting the sample with a compound or an agent capable of detecting a nucleic acid (e.g., mRNA, genomic RNA) of the N-gene of the hSARS virus such that the presence of the N-gene is detected in the sample. In preferred embodiments, the N-gene may be detected using a labeled nucleic acid probe comprising of the nucleotide sequence of SEQ ID NO:2471, complement thereof, or a portion thereof. The portion may be 10, 20, 30, 40, 50, 100, 200, 400, 500, 600, 800, 1000, 1200 nucleotides in length. In preferred embodiments, primers comprising nucleotide sequence of SEQ ID NOS:2475 and/or 2476 or SEQ ID NOS:2480 and/or 2481 may be used to amplify a portion of the N-gene for detection.

A preferred agent for detecting hSARS mRNA or genomic RNA of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic RNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a nucleic acid molecule comprising or consisting of the nucleotide sequence or SEQ ID NO:1, 11, 13, 15, 2471 or 2473, complement thereof, or a portion thereof, such as an oligonucleotide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1000 or more contiguous nucleotides in length and sufficient to specifically hybridize under stringent conditions to a hSARS mRNA or genomic RNA.

In another preferred specific embodiment, the presence of N-gene is detected in the sample by an reverse transcription polymerase chain reaction (RT-PCR) using the primers that are constructed based on a partial nucleotide sequence of the N-gene or a genomic nucleic acid sequence of SEQ ID NO:15, or based on a nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471 or 2473. In a non-limiting specific embodiment, preferred primers to be used in a RT-PCR method are 5'-TACACACTCGC-GTTG-3' (SEQ ID NO:3) and/or 5'-CAGCAAGTCGACG-AAT-3' (SEQ ID NO:4), in the presence of 2.5 mM MgCl2, and the thermal cycles are, for example, but not limited to, 94°C for 8 min followed by 40 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min (also see Sections 6.7 and 6.8 infra). In preferred embodiments, the primers comprise nucleic acid sequence of SEQ ID NOS:2475 and 2476. In another preferred embodiment, the primers comprise nucleic acid sequence of SEQ ID NOS: 2480 and 2481. In preferred embodiments, the thermal cycles are 94°C for 10 min followed by 40 cycles of 94°C for 30 seconds, 56°C for 30 seconds, 72°C for 30 seconds, 72°C for 10 minutes. In another preferred embodiment, the thermal cycles are 94°C for 3 min followed by 40 cycles of 94°C for 30 seconds, 56°C for 30 seconds, 72°C for 30 seconds, 72°C for 10 minutes. In more preferred specific embodiment, the present invention provides a real-time quantitative PCR assay to detect the presence of hSARS virus in a biological sample by subjecting the cDNA obtained by reverse transcription of the extracted total RNA from the sample to PCR reactions using the specific primers, such as those having nucleotide sequences of SEQ ID NOS:3 and 4, and a fluoresence dye, such as SYBR Green I, which fluoresces when bound non-specifically to double-stranded DNA. The fluorescence signals from these reactions are captured at the end of extension steps as PCR product is generated over a range of the thermal cycles, thereby allowing the quantitative determination of the viral load in the sample based on an amplification plot (see Section 6.7, infra).

In the preferred embodiment, the present invention provides a method for detecting the presence or absence of nucleic acid of the S-gene in a biological sample. The method involves obtaining a biological sample from various sources and contacting the sample with a compound or an agent capable of detecting a nucleic acid (e.g., mRNA, genomic RNA) of the S-gene of the hSARS virus such that the presence of the S-gene is detected in the sample. A preferred agent for detecting hSARS mRNA or genomic RNA of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic RNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a nucleic acid molecule comprising or consisting of the nucleotide sequence or SEQ ID NO:1, 11, 13, 15, 2471, or 2473, or a portion thereof, such as an oligonucleotide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1000 or more contiguous nucleotides.
in length and sufficient to specifically hybridize under stringent conditions to a siSARS mRNA or genomic RNA.

In another preferred specific embodiment, the presence of S-gene is detected in the sample by an reverse transcription polymerase chain reaction (RT-PCR) using the primers that are constructed based on a partial nucleotide sequence of the S-gene (SEQ ID NO:2473).

In vitro techniques for detection of mRNA include northern hybridizations, in situ hybridizations, RT-PCR, and RNase protection. In vitro techniques for detection of genomic RNA include northern hybridizations, RT-PCR, and RNase protection.

The polynucleotides encoding the N-gene may be amplified before they are detected. The term “amplified” refers to the process of making multiple copies of the nucleic acid from a single polynucleotide molecule. The amplification of polynucleotides can be carried out in vitro by biochemical processes known to those of skill in the art. The amplification agent may be any compound or system that will function to accomplish the synthesis of primer extension products, including enzymes. Suitable enzymes for this purpose include, for example, E. coli DNA polymerase I, Taq polymerase, Klenow fragment of E. coli DNA polymerase I, T4 DNA polymerase, other available DNA polymerases, polymerase mutants, reverse transcriptase, ligase, and other enzymes, including heat-stable enzymes (i.e., those enzymes that perform primer extension after being subjected to temperatures sufficiently elevated to cause denaturation). Suitable enzymes will facilitate combination of the nucleotides in the proper manner to form the primer extension products that are complementary to each mutant nucleotide strand. Generally, the synthesis will be initiated at the 3'-end of each primer and proceed in the 5'-direction along the template strand, until synthesis terminates, producing molecules of different lengths. There may be amplification agents, however, that initiate synthesis at the 5'-end and proceed in the other direction, using the same process as described above. In any event, the method of the invention is not to be limited to the embodiments of amplification described herein.

One method of in vitro amplification, which can be used according to this invention, is the polymerase chain reaction (PCR) described in U.S. Pat. Nos. 4,683,202 and 4,683,195. The term “polymerase chain reaction” refers to a method for amplifying a DNA base sequence using a heat-stable DNA polymerase and two oligonucleotide primers, one complementary to the (5')-strand at one end of the sequence to be amplified and the other complementary to the (3')-strand at the other end. Because the newly synthesized DNA strands can subsequently serve as templates for the same primer sequences, successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. The polymerase chain reaction is used to detect the presence of polynucleotides encoding cytokines in the sample. Many polymerase chain methods are known to those of skill in the art and may be used in the method of the invention. For example, DNA can be subjected to 30 to 35 cycles of amplification in a thermocycler as follows: 95°C for 30 sec, 52°C to 60°C for 1 min, and 72°C for 1 min, with a final extension step of 72°C for 5 min. For another example, DNA can be subjected to 35 polymerase chain reaction cycles in a thermocycler at a denaturing temperature of 95°C for 30 sec, followed by varying annealing temperatures ranging from 54-58°C for 1 min, an extension step at 70°C for 1 min and a final extension step at 70°C.

The primers for use in amplifying the N-gene or S-gene of the invention may be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof so long as the primers are capable of hybridizing to the polynucleotides of interest. One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition. The primer must prime the synthesis of extension products in the presence of the inducing agent for amplification.

Primers used according to the method of the invention are complementary to each strand of nucleotide sequence to be amplified. The term “complementary” means that the primers must hybridize with their respective strands under conditions, which allow the agent for polymerization to function. In other words, the primers that are complementary to the flanking sequences hybridize with the flanking sequences and permit amplification of the nucleotide sequence. Preferably, the 3' terminus of the primer that is extended has perfectly base paired complementarity with the complementary flanking strand. Primers and probes for polynucleotides encoding N-gene or S-gene of the present invention can be developed using known methods combined with the present disclosure. Those of ordinary skill in the art will know of various amplification methodologies that can also be utilized to increase the copy number of target nucleic acid. The polynucleotides detected in the method of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific nucleic acid sequence such as another polymerase chain reaction, oligonucleotide restriction (Saiki et al., BioTechnology 3:1008-1012 (1985)), allele-specific oligonucleotide (ASO) probe analysis (Comer et al., Proc. Natl. Acad. Sci. USA 80: 278 (1983), oligonucleotide ligation assays (OLAs) (Landegren et al., Science 241:1077 (1988)), RNAse Protection Assay and the like. Molecular techniques for DNA analysis have been reviewed (Landegren et al, Science 242: 229-237 (1988)). Following DNA amplification, the reaction product may be detected by Southern blot analysis, without using radioactive probes. In such a process, for example, a small sample of DNA containing the polynucleotides obtained from the tissue or subject are amplified, and analyzed via a Southern blotting technique. The use of non-radioactive probes or labels is facilitated by the high level of the amplified signal. In one embodiment of the invention, one nucleoside triphosphate is radioactively labeled, thereby allowing direct visualization of the amplification product by autoradiography. In another embodiment, amplification primers are fluorescently labeled and run through an electrophoresis system. Visualization of amplified products is by laser detection followed by computer assisted graphic display, without a radioactive signal.

The methods of the present invention can involve a real-time quantitative PCR assay, such as a Taqman assay (Holland et al., Proc Natl Acad Sci USA, 88(16):7276 (1991); also see U.S. patent application of U.S. application Ser. No. 10/808,187 filed Mar. 24, 2004, which is incorporated by reference in its entirety). The assays can be performed on an instrument designed to perform such assays, for example those available from Applied Biosystems (Foster City, Calif.). Primers and probes for such an assay are designed according to known procedures in the art.

The size of the primers used to amplify a portion of the N-gene or S-gene is at least 10, 15, 20, 25, 30 nucleotide in length. In particular, primers that amplify the N-gene or S-gene is most preferred. Preferably, the GC ratio should be above 30, 35, 40, 45, 50, 55, 60% so as to prevent hairpin
structure on the primer. Furthermore, the amplicon should be sufficiently long enough to be detected by standard molecular biology methodologies.

Preferably, the amplicon is at least 40, 60, 100, 200, 300, 400, 500, 600, 800, 1000 base pair in length. In a specific embodiment, the methods further involve obtaining a control sample from a control subject, contacting the control sample with a compound or agent capable of detecting N-gene or S-gene; such that the presence of mRNA or genomic RNA encoding the N-gene or S-gene is detected in that sample, and comparing the presence (or absence) of N-gene or S-gene; or mRNA or genomic RNA encoding the polypeptide in the control sample with the presence of N-gene or S-gene; or mRNA or genomic DNA encoding the polypeptide in the test sample.

The invention also encompasses kits for detecting the presence of N-gene nucleic acid in a test sample. The kit, for example, can comprise a labeled compound or agent capable of detecting a nucleic acid molecule encoding the polypeptide in a test sample and, in certain embodiments, a means for determining the amount of mRNA in the sample (an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide).

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or to a sequence within the N-gene; (2) a pair of primers useful for amplifying a nucleic acid molecule containing the N-gene sequence. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assured and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for use.

The present invention relates to the isolated N-gene and S-gene of the hSARS virus. In a specific embodiment, the virus comprises a nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471, and/or 2473. In a specific embodiment, the present invention provides isolated nucleic acid molecules of the hSARS virus, comprising, or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471, and/or 2473, a complement thereof or a portion thereof. In another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 11, 13, 15, 2471, and/or 2473, or specific genes of known member of Coronaviridae, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2471, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2473, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. The polypeptides include those shown in FIGS. 11 (SEQ ID NO:17-239, 241-736 and 738-1107) and 12 (SEQ ID NO:1109-1589, 1591-1964 and 1966-2470) or having an amino acid sequence of SEQ ID NO:2472 or 2474. The polypeptides or the proteins of the present invention preferably have one or more biological activities of the proteins encoded by the sequence of SEQ ID NO:1, 11, 13, 15, 2471 or 2473, or the polypeptides shown in FIGS. 11 and 12, or the native viral proteins containing the amino acid sequences encoded by the sequence of SEQ ID NO:1, 11, 13, 15, 2471 or 2473.

The present invention also relates to a method for propagating the hSARS virus in host cells. The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides the entire nucleotide sequence of hSARS virus, CCTCC-V200303, SEQ ID NO:15, or fragments, or complement thereof. Furthermore, the present invention relates to a nucleic acid molecule that hybridizes any portion of the genome of the hSARS virus, CCTCC-V200303, or SEQ ID NO:15, under the stringent conditions. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471 or 2473, or a complement thereof, or a portion thereof. In specific embodiments, the primers comprise nucleotide sequence of SEQ ID NO:2475, 2476, 2477, 2478, 2480 and 2481. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for use as hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention, consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 2471 or 2473, a complement thereof, or a portion thereof. The invention further relates to a kit comprising primers having nucleic acid sequence of SEQ ID NOS:2475 and 2476; and SEQ ID
NOS:2480 and 2481, for the detection of N-gene. In another embodiment, the invention relates to a kit comprising primers having nucleic acid sequence of SEQ ID NOS:2477 and/or 2478 for the detection of S-gene. In a preferred embodiment, the kit further comprises reagents for the detection of genes not found in hSARS virus as a negative control. The invention further encompasses chimeric or recombinant viruses or viral proteins encoded by said nucleotide sequences.

The invention further provides antibodies that specifically bind a polypeptide having amino acid sequence of SEQ ID NO:2472 or 2474. The invention further provides antibodies that specifically bind the polypeptides of the invention encoded by the nucleotide sequence of SEQ ID NO:15, or the polypeptides shown in FIGS. 11 and 12, or a fragment thereof, or any hSARS epitope. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab)2 fragments, disulfide-linked Fv, intrabodies and fragments containing either a Vλ or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the hSARS virus of the invention in a biological material, such as cells, blood, saliva, urine, sputum, nasopharyngeal aspirates, and so forth. The presence of the hSARS virus in a sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence of the hSARS virus. In a specific embodiment, the detection agents are the antibodies of the present invention. In another embodiment, the detection agent is a nucleic acid of the present invention.

In another embodiment, the invention provides vaccine preparations comprising the hSARS virus, including recombinant and chimeric forms of said virus, or subunits of the virus. In a specific embodiment, the vaccine preparations comprise live but attenuated hSARS virus with or without pharmaceutically acceptable excipients, including adjuvants. In another specific embodiment, the vaccine preparations comprise an inactivated or killed hSARS virus with or without pharmaceutically acceptable excipients, including adjuvants. The vaccine preparations of the present invention may further comprise with adjuvants or adjuvants. Accordingly, the present invention further provides methods of preparing recombinant or chimeric forms of hSARS. In another specific invention, the vaccine preparations of the present invention comprise one or more nucleic acid molecules comprising or consisting of the sequence of SEQ ID NO:1, 11, 13, 15, 2471 and/or 2473, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 11, 13, 2471 and/or 2473, or the polypeptides shown in FIGS. 11 and 12, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:15, or a fragment thereof. Furthermore, the present invention provides methods for treating, ameliorating, managing, or preventing SARS by administering the vaccine preparations or antibodies of the present invention alone or in combination with antivirals [e.g., amantadine, rimantadine, gancyclovir, acyclovir, ribavirin, penciclovir, oseltamivir, foscarnet zidovudine (AZT), didanosine (ddI), lamivudine (3TC), zalcitabine (ddC), stavudine (d4T), nevirapine, delavirdine, indinavir, ritonavir, vidarabine, nelfinavir, saquinavir, relenza, tamiflu, pleconaril, interferons, etc.], steroids and corticosteroids such as prednisone, cortisone; fluticasone and glucocorticoid, antibiotics, analgesics, bronchodilators, or other treatments for respiratory and/or viral infections.

Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The present invention also provides kits comprising pharmaceutical compositions of the present invention.

In another aspect, the present invention provides methods for screening anti-viral agents that inhibit the infectivity or replication of hSARS virus or variants thereof.

5.1 Recombinant and Chimeric hSARS Viruses

The invention encompasses recombinant or chimeric viruses encoded by viral vectors derived from the genome of hSARS virus or natural variants thereof. In a specific embodiment, a recombinant virus is one derived from the hSARS virus of deposit accession no. CCTCC-V200303. In a specific embodiment, the virus has a nucleotide sequence originating from the hSARS virus, or a fragment thereof. In another specific embodiment, a recombinant virus is one derived from a natural variant of hSARS virus. A natural variant of hSARS has a sequence that is different from the genomic sequence (SEQ ID NO:15) of the hSARS virus, CCTCC-V200303, due to one or more naturally occurring mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a phenotypic change. In accordance with the present invention, a viral vector which is derived from the genome of the hSARS virus, CCTCC-V200303, is one that contains a nucleic acid sequence that encodes at least a part of one ORF of the hSARS virus. In a specific embodiment, the ORF comprises or consists of a nucleotide sequence of SEQ ID NO:1, 11, 13, 2471, 2473, or a fragment thereof. In a specific embodiment, there are more than one ORF within the nucleotide sequence of SEQ ID NO:15, as shown in FIGS. 11 (SEQ ID NOS:16, 240 and 737) and 12 (SEQ ID NOS:1108, 1590 and 1065), or a fragment thereof. In another embodiment, the polypeptide encoded by the ORF comprises or consists of an amino acid sequence of SEQ ID NO:2, 12, 14, 2472, 2474, or a fragment thereof, or shown in FIGS. 11 (SEQ ID NOS:17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS:1109-1589, 1591-1964 and 1966-2470), or a fragment thereof. In accordance with the present invention these viral vectors may or may not include nucleic acids that are non-native to the viral genome.

In another specific embodiment, a chimeric virus of the invention is a recombinant hSARS virus which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous or native nucleotide sequences have been replaced with heterologous nucleotide sequences.

According to the present invention, the chimeric viruses are encoded by the viral vectors of the invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance with the invention a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences. In accordance with the present invention, the chimeric viruses may be
encoded by nucleotide sequences derived from different strains or variants of hSARS virus. In particular, the chimeric virus is encoded by nucleotide sequences that encode antigenic polypeptides derived from different strains or variants of hSARS virus.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., J. Virol. 72, 2955-2961; Durbin et al., 2000, J. Virol. 74, 6821-6831; Skladopoulos et al., 1998, J. Virol. 72, 1762-1768 (1998); Teng et al., 2000, J. Virol. 74, 9317-9321). For example, it can be envisaged that a virus vector derived from the hSARS virus expressing one or more proteins of variants of hSARS virus, or vice versa, will protect a subject vaccinated with such vector against infections by both the native hSARS and the variant. Attenuated and replication-defective viruses may be of use for vaccination purposes with live vaccines as has been suggested for other viruses. (See, PCT WO 02/057302, at pp. 6 and 23, incorporated by reference herein).

In accordance with the present invention the heterologous sequence to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include sequences obtained or derived from different strains or variants of hSARS virus. In certain embodiments, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the chimeric viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more heterologous sequences have been inserted or added to the vector. The selection of the viral vector may depend on the species of the subject that is to be treated or protected from a viral infection. If the subject is human, then an attenuated hSARS virus can be used to provide the antigenic sequences.

In accordance with the present invention, the viral vectors can be engineered to provide antigenic sequences which confer protection against infection by the hSARS and natural variants thereof. The viral vectors may be engineered to provide one, two, three or more antigenic sequences. In accordance with the present invention the antigenic sequences may be derived from the same virus, from different strains or variants of the same type of virus, or from different viruses. The expression products and/or recombinant or chimeric virions obtained in accordance with the invention may advantageously be utilized in vaccine formulations. The expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral and bacterial antigens, tumor antigens, allergen antigens, and auto-antigens involved in autoimmune disorders. In particular, the chimeric virions of the present invention may be engineered to create vaccines for the protection of a subject from infections with hSARS virus and variants thereof.

In certain embodiments, the expression products and recombinant or chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens, and auto-antigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing hSARS genes to contain foreign sequences in their respective external domains. Where the heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune response against the disease agent from which these determinants are derived.

Thus, the present invention relates to the use of viral vectors and recombinant or chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens. The present invention also encompasses recombinant viruses comprising a viral vector derived from the hSARS or variants thereof which contains sequences which result in a virus having a phenotype more suitable for use in vaccine formulations, e.g., attenuated phenotype or enhanced antigenicity. The modifications and modifications can be in coding regions, in intergenic regions and in the leader and trailer sequences of the virus.

The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of hSARS virus are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the hSARS genome will be generated in prokaryotic cells for the expression of viral nucleic acids in vitro or in vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, which lack parts of the viral genome for the generation of replication-defective viruses, and may contain mutations, deletions or insertions for the generation of attenuated viruses. In addition, the present invention provides a host cell infected with hSARS virus, for example, of deposit no. CCTCC-V200303.

Infectious copies of hSARS (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.

In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial hSARS proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

The viral vectors and chimeric viruses of the present invention may be used to modulate a subject's immune system by stimulating a humoral immune response, a cellular immune response or by stimulating tolerance to an antigen. As used herein, a subject means: humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents.

5.2 Formulation of Vaccines and Antivirals

In the preferred embodiment, the invention provides a proteinaceous molecule or hSARS virus specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from the virus according to the invention, including envelope protein E, integral membrane protein M, spike protein S, nucleocapsid protein N, hemagglutinin esterase H, and RNA-dependent RNA polymerase. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as subunit vaccines. Particularly useful are polypeptides encoded by the nucleotide sequence of SEQ ID NO: 1, 11, 13, 15, 2471, 2473, or as shown in FIG. 11 (SEQ ID NO: 17-239, 241-736 and 738-1107) and FIG. 12 (SEQ ID NO: 1109-1589, 1591-1964 and 1966-2470), or having the amino acid sequence of SEQ ID NO: 2472 or 2474, or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments of
the hSARS genome, of course preferred are those that are within the preferred bounds and metes of ORFs, in particular, for eliciting hSARS specific antibody or T cell responses, whether in vivo (e.g. for protective or therapeutic purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

The invention provides vaccine formulations for the prevention and treatment of infections with hSARS virus. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the hSARS virus. In certain embodiments, the virus is attenuated.

In another embodiment of this aspect of the invention, inactivated vaccine formulations may be prepared using conventional techniques to “kill” the chimeric viruses. Inactivated vaccines are “dead” in the sense that their infectivity has been destroyed. Ideally, the infectivity of the virus is destroyed without affecting its immunogenicity. In order to prepare inactivated vaccines, the chimeric virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by formaldehyde or β-propiolactone, and pooled. The resulting vaccine is usually inculcated intramuscularly.

Inactivated viruses may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include but are not limited to mineral gels, e.g., aluminum hydroxide; surface active substances such as losolectin, pluronic polylons, polyanions; oil emulsions; and potentially useful human adjuvants such as BCG and Corynebacterium parvum.

In another aspect, the present invention also provides DNA vaccine formulations comprising a nucleic acid or fragment of the hSARS virus, e.g., the virus having accession no. CCTCCV200303, or nucleic acid molecules having the sequence of SEQ ID NO.1, 11, 13, 15, 2471, 2475, or a fragment thereof. In another specific embodiment, the DNA vaccine formulations of the present invention comprises a nucleic acid or fragment thereof encoding the antibodies which immunospecifically binds hSARS viruses. In DNA vaccine formulations, a vaccine DNA comprises a viral vector, such as that derived from the hSARS virus, bacterial plasmid, or other expression vector, bearing an insert comprising a nucleic acid molecule of the present invention operably linked to one or more control elements, thereby allowing expression of the vaccinating proteins encoded by said nucleic acid molecule in a vaccinated subject. Such vectors can be prepared by recombinant DNA technology as recombinant or chimeric viral vectors carrying a nucleic acid molecule of the present invention (see also Section 5.1, supra).


Many methods may be used to introduce the vaccine formulations described above. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes. Alternatively, it may be preferable to introduce the chimeric virus vaccine formulation via the natural route of infection of the patient for which the vaccine is designed. The DNA vaccines of the present invention may be administered in saline solutions by injections into muscle or skin using a syringe and needle (Wolff J. A. et al., 1990, Direct gene transfer into mouse muscle in vivo, Science 247:1465-1468; Raz, E., 1994, Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses, Proc. Natl. Acad. Sci. USA 91:9519-9523). Another way to administer DNA vaccines is called “gene gun” method, whereby microprojectile gold beads coated with the DNA molecules of interest is fired into the cells (Tang, D. et al., 1992, Genetic immunization is a simple method for eliciting an immune response, Nature 356:152-154). For general reviews of the methods for DNA vaccines, see Robinson, H. L., 1999, DNA vaccines: basic mechanism and immune responses (Review), Int. J. Mol. Med. 4(5):459-555; Barber, B., 1997, Introduction: Emerging vaccine strategies, Seminars in Immunology 9(5): 269-270; and Robinson, H. L. et al., 1997, DNA vaccines, Seminars in Immunology 9(5):271-283.

5.3 Attenuation of hSARS Virus or Variants Thereof
The hSARS virus or variants thereof of the invention can be genetically engineered to exhibit an attenuated phenotype. In particular, the viruses of the invention exhibit an attenuated phenotype in a subject to which the virus is administered as a vaccine. Attenuation can be achieved by any method known to a skilled artisan. Without being bound by theory, the attenuated phenotype of the viruses of the invention can be caused, e.g., by using a virus that naturally does not replicate well in an intended host species, for example, by reduced replication of the viral genome, by reduced ability of the virus to infect a host cell, or by reduced ability of the viral proteins to assemble to an infectious viral particle relative to the wild type strain of the virus.

The attenuated phenotypes of hSARS virus or variants thereof can be tested by any method known to the artisan. A candidate virus can, for example, be tested for its ability to infect a host or for the rate of replication in a cell culture system. In certain embodiments, growth curves at different temperatures are used to test the attenuated phenotype of the virus. For example, an attenuated virus is able to grow at 35°C, but not at 39°C or 40°C. In certain embodiments,
different cell lines can be used to evaluate the attenuated phenotype of the virus. For example, an attenuated virus may only be able to grow in monkey cell lines but not the human cell lines, or the achievable virus titers in different cell lines are different for the attenuated virus. In certain embodiments, viral replication in the respiratory tract of a small animal model, including but not limited to, hamsters, cotton rats, mice and guinea pigs, is used to evaluate the attenuated phenotypes of the virus. In other embodiments, the immune response induced by the virus, including but not limited to, the antibody titers (e.g., assayed by plaque reduction neutralization assay or ELISA) is used to evaluate the attenuated phenotypes of the virus. In a specific embodiment, the plaque reduction neutralization assay or ELISA is carried out at a low dose. In certain embodiments, the ability of the hSARS virus to elicit pathological symptoms in an animal model can be tested. A reduced ability of the virus to elicit pathological symptoms in an animal model is indicative of its attenuated phenotype. In a specific embodiment, the candidate viruses are tested in a mouse model for nasal infection, indicated by mucous production.

The viruses of the invention can be attenuated such that one or more of the functional characteristics of the virus are impaired. In certain embodiments, attenuation is measured in comparison to the wild type strain of the virus from which the attenuated virus is derived. In other embodiments, attenuation is determined by comparing the growth of an attenuated virus in different host systems. Thus, for a non-limiting example, hSARS virus or a variant thereof is said to be attenuated when grown in a human host if the growth of the hSARS or variant thereof in the human host is reduced compared to the non-attenuated hSARS or variant thereof.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host, is capable of replicating in a host such that infectious viral particles are produced. In comparison to the wild type strain, however, the attenuated strain grows to lower titers or grows more slowly. Any technique known to the skilled artisan can be used to determine the growth curve of the attenuated virus and compare it to the growth curve of the wild type virus.

In certain embodiments, the attenuated virus of the invention (e.g., a recombinant or chimieic hSARS) cannot replicate in human cells as well as the wild type virus (e.g., wild type hSARS) does. However, the attenuated virus can replicate well in a cell line that lacks interferon functions, such as Vero cells.

In other embodiments, the attenuated virus of the invention is capable of infecting a host, of replicating in the host, and of causing proteins of the virus of the invention to be inserted into the cytoplasmic membrane, but the attenuated virus does not cause the host to produce new infectious viral particles. In certain embodiments, the attenuated virus infects the host, replicates in the host, and causes viral proteins to be inserted in the cytoplasmic membrane of the host with the same efficiency as the wild type hSARS. In other embodiments, the ability of the attenuated virus to cause viral proteins to be inserted into the cytoplasmic membrane into the host cell is reduced compared to the wild type virus. In certain embodiments, the ability of the attenuated hSARS virus to replicate in the host is reduced compared to the wild type virus. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a mammalian cell, of replicating within the host, and of causing viral proteins to be inserted into the cytoplasmic membrane of the host.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host. In contrast to the wild type hSARS, however, the attenuated hSARS cannot be replicated in the host. In a specific embodiment, the attenuated hSARS virus infects a host and can cause the host to insert viral proteins in its cytoplasmic membranes, but the attenuated virus is incapable of being replicated in the host. Any method known to the skilled artisan can be used to test whether the attenuated hSARS has infected the host and has caused the host to insert viral proteins in its cytoplasmic membranes.

In certain embodiments, the ability of the attenuated virus to infect a host is reduced compared to the ability of the wild type virus to infect the same host. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a host.

In certain embodiments, mutations (e.g., missense mutations) are introduced into the genome of the virus, for example, into the sequence of SEQ ID NO:1, 11, 13, 15, 2471 or 2473, or to generate a virus with an attenuated phenotype. Mutations (e.g., missense mutations) can be introduced into the structural genes and/or regulatory genes of the hSARS. Mutations can be additions, substitutions, deletions, or combinations thereof. Such variant of hSARS can be screened for a predicted functionality, such as infectivity, replication ability, protein synthesis ability, assembling ability, as well as cytopathic effect in cell cultures. In a specific embodiment, the missense mutation is a cold-sensitive mutation. In another embodiment, the missense mutation is a heat-sensitive mutation. In another embodiment, the missense mutation prevents a normal processing or cleavage of the viral proteins.

In other embodiments, deletions are introduced into the genome of the hSARS virus, which result in the attenuation of the virus.

In certain embodiments, attenuation of the virus is achieved by replacing a gene of the wild type virus with a gene of a virus of a different species, of a different subgroup, or of a different variant. In another aspect, attenuation of the virus is achieved by replacing one or more specific domains of a protein of the wild type virus with domains derived from the corresponding protein of a virus of a different species. In certain other embodiments, attenuation of the virus is achieved by deleting one or more specific domains of a protein of the wild type virus.

When a live attenuated vaccine is used, its safety must also be considered. The vaccine must not cause disease. Any techniques known in the art that can make a vaccine safe may be used in the present invention. In addition to attenuation techniques, other techniques may be used. One non-limiting example is to use a soluble heterologous gene that cannot be incorporated into the virion membrane. For example, a single copy of the soluble version of a viral transmembrane protein lacking the transmembrane and cytosolic domains thereof, can be used.

Various assays can be used to test the safety of a vaccine. For example, sucrase gradients and neutralization assays can be used to test the safety. A sucrase gradient assay can be used to determine whether a heterologous protein is inserted in a virion. If the heterologous protein is inserted in the virion, the virion should be tested for its ability to cause symptoms in an appropriate animal model since the virus may have acquired new, possibly pathological, properties.

5.4 Adjuvants and Carrier Molecules
hSARS-associated antigens are administered with one or more adjuvants. In one embodiment, the hSARS-associated antigen is administered together with a mineral salt adjuvants or mineral salt gel adjuvant. Such mineral salt and mineral salt gel adjuvants include, but are not limited to, aluminum
hydroxide (AL:HYDROGEL, REHYDROGEL), aluminum phosphate gel, aluminum hydroxyphosphate (ADJU-PHOS), and calcium phosphate.

In another embodiment, hSARS-associated antigen is administered with an immunostimulatory adjuvant. Such class of adjuvants, include, but are not limited to, cytokines (e.g., interleukin-2, interleukin-7, interferon-\(\gamma\)), interferon-\(\gamma\)-induced protein 10 (IP-10), and IL-12 peptide or Sclavo Peptide), cytokine-containing liposomes, triterpenoid glycosides or saponins (e.g., QuillA and QS-21), also sold under the trademark STIMULON, ISOCOPREP, Muramyl Dipeptide (MDP) derivatives, such as N-acetyl-muramyl-L-threonyl-D-isoglutamine (Threonyl-MDP), sold under the trademark TERMMURTIDE), GMDP, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(\'\(\alpha\)2,6-di-O-mannosyl-sucrose)-3-hydroxy-phosphoryloxy)-ethylamine, muramyl tripeptide phosphodiesteramidolamine (MTP-PE), unmethylated CpG dinucleotides and oligonucleotides, such as bacterial DNA and fragments thereof, LPS, monophosphoryl lipid A (3D-MLA sold under the trademark MPL), and polyphosphazenes.

In another embodiment, the adjuvant used is a particular adjuvant, including, but not limited to, emulsions, e.g., Freund’s Complete Adjuvant, Freund’s Incomplete Adjuvant, squalene or squalane oil-in-water adjuvant formulations, such as SAF and MF59, e.g., prepared with block-copolymers, such as L-121 (polyoxypropylene/polyoxyethylene) sold under the trademark PLURONIC L-121, Liposomos, Virosomes, coeheletes, and immune stimulating complex, which is sold under the trademark ISCOM.

In another embodiment, a microparticulate adjuvant is used, Microparticulate adjuvants include, but are not limited to biodegradable and biocompatible polyesters, homo- and copolymers of lactic acid (PLA) and glycolic acid (PGA), poly(lactide-co-glycolides) (PLGA), microparticles, polymers that self-assemble into particulates (poloxamer particles), soluble polymers (polyphosphazenes), and virus-like particles (VLPs) such as recombinant protein particles, e.g., hepatitis B surface antigen (HbsAg).

Yet another class of adjuvants that may be used include mucosal adjuvants, including but not limited to heat-labile enterotoxin from Escherichia coli (LT), cholera holotoxin (CT) and cholera Toxin B Subunit (CTB) from Vibriob cholerae, mutant toxins (e.g., LTK63 and LTK72), microparticles, and polymerized liposomes.

In other embodiments, any of the above classes of adjuvants may be used in combination with each other or with other adjuvants. For example, non-limiting examples of combination adjuvant preparations that can be used to administer the hSARS-associated antigens of the invention include liposomes containing immunostimulatory protein, cytokines, or T-cell and/or B-cell peptides, or microbes with or without entrapped IL-2 or microparticles containing enterotoxin. Other adjuvants known in the art are also included within the scope of the invention (see Vaccine Design: The Subunit and Adjuvant Approach, Chap. 7, Michael F. Powell and Mark J. Newman (eds.), Plenum Press, New York, 1995, which is incorporated herein in its entirety).

The effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed against an immunogenic polypeptide containing a hSARS polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various hSARS proteins.

The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid additional salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The patient to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats.

5.5 Preparation of Antibodies

Antibodies which specifically recognize a polypeptide of the invention, such as, but not limited to, polypeptides comprising the sequence of SEQ ID NO:2, 13, 14, 2472, 2474, and polypeptides as shown in FIGS. 11 (SEQ ID NO:17-239, 241-376 and 738-1107) and 12 (SEQ ID NO:1109-1589, 1591-1694 and 1666-2470), or hSARS epitope or antigen-binding fragments thereof can be used for detecting, screening, and isolating the polypeptide of the invention or fragments thereof, or similar sequences that might encode similar enzymes from the other organisms. For example, in one specific embodiment, an antibody which immunospecifically binds hSARS epitope, or a fragment thereof, can be used for various in vitro detection assays, including enzyme-linked immunosorbent assays (ELISA), radioimmunosassays, Western blot, etc., for the detection of a polypeptide of the invention or, preferably, hSARS, in samples, for example, a biological material, including cells, cell culture media (e.g., bacterial cell culture media, mammalian cell culture media, insect cell culture media, yeast cell culture media, etc.), blood, plasma, serum, tissues, sputum, naseopharyngeal aspirates, etc.

Antibodies specific for a polypeptide of the invention or any epitope of hSARS may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest, for example, the hSARS virus from deposit no. CCTCC-V200303, or comprises a nucleotide sequence of SEQ ID NO:15, can be produced by various procedures well known in the art. For example, an antigen can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc., to induce the production of antiserum containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund’s (complete and incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as hyaluronic, pluronics, polyethylene, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful adjuvants for humans such as BCG (Bacille Calmette-Guerin) and Corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a
combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas, pp. 563-681 (Elsevier, N.Y., 1981) (both of which are incorporated by reference in their entitlements). The term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology. The term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized with an antigen of interest or a cell expressing such an antigen. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and spleenocytes isolated. The spleenocytes are then fused by well known techniques to any suitable myeloma cells. Hybridomas are selected and cloned by limiting dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding the antigen. Ascites fluid, which generally contains high levels of antibodies, can be generated by injecting mice intraperitoneally with positive hybridoma clones.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab)’ fragments may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab)’ fragments). F(ab)’ fragments contain the complete light chain, and the variable region, the CH1 region and the hinge region of the heavy chain. The antibodies of the invention or fragments thereof can also be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

The nucleotide sequence encoding an antibody may be obtained from any information available to those skilled in the art (i.e., from Genbank, the literature, or by routine cloning and sequence analysis). If a clone containing a nucleic acid encoding a particular antibody or an epitope-binding fragment thereof is not available, but the sequence of the antibody molecule or epitope-binding fragment thereof is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using synthetic primers hybridizable to the 3’ and 5’ ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicative cloning vectors using any method well known in the art.

Once the nucleotide sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., supra; andAusubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entitlements), to generate antibodies having a different amino acid sequence by, for example, introducing amino acid substitutions, deletions, and/or insertions into the epitope-binding domain regions of the antibodies or any portion of antibodies which may enhance or reduce biological activities of the antibodies.

Recombinant expression of an antibody requires construction of an expression vector containing a nucleotide sequence that encodes the antibody. Once a nucleotide sequence encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art as discussed in the previous sections. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The nucleotide sequence encoding the heavy-chain variable region, light-chain variable region, both the heavy-chain and light-chain variable regions, an epitope-binding fragment of the heavy- and/or light-chain variable region, or one or more complementarily determining regions (CDRs) of an antibody may be cloned into such a vector for expression. Thus-prepared expression vector can be then introduced into appropriate host cells for the expression of the antibody. Accordingly, the invention includes host cells containing a polynucleotide encoding an antibody specific for the polypeptides of the invention or fragments thereof.

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides or different selectable markers to ensure maintenance of both plasmids. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature, 322:52, 1986; and Kohler, Proc. Natl. Acad. Sci. USA, 77:2 197, 1980). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

In another embodiment, antibodies can also be generated using various pluge display methods known in the art. In pluge display methods, functional antibody domains are displayed on the surface of pluge particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such pluge can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Pluge expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Pluge used in these methods are typically filamentous pluge, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the pluge gene III or gene VIII protein. Examples of pluge display methods that can be used to make the immunoglobulins, or fragments thereof, of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods, 182:41-50, 1995; Ames et al., J. Immunol. Methods, 184:177-186, 1995; Kettleborough et al., Eur. J. Immunol., 24:952-958.
Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology, 28(4):849-498, 1991; Studnicka et al., Protein Engineering, 7(6):805-814, 1994; Roguska et al., Proc Natl. Acad. Sci. USA, 91:969-973, 1994), and chain shuffling (U.S. Pat. No. 5,565,332), all of which are hereby incorporated by reference in their entirety.

Complete human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol., 13:65-93, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, Calif.), Medarex (NJ) and Genpharm (San Jose, Calif.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jesper et al., Bio/technology, 12:809-903, 1998).

Antibodies fused or conjugated to heterologous polypeptides may be used in in vitro immunoassays and in purification methods (e.g., affinity chromatography) well known in the art. See e.g., PCT publication Number WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett., 39:91-99, 1994; U.S. Pat. No. 5,474,981; Gillies et al., PNAS, 89:1428-1432, 1992; and Fell et al., J. Immunol., 146:2446-2452, 1991, which are incorporated herein by reference in their entirety.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the polypeptides of the invention or fragments, derivatives, analogs, or variants thereof, or similar molecules having the similar enzymatic activities as the polypeptide of the invention. Such solid supports include, but are not limited to, glass, cellulose, polycrylamide, nylon, polystyrene, polystyrene chloride or polypropylene.

5.6 Pharmaceutical Compositions and Kits

The present invention encompasses pharmaceutical compositions comprising anti-viral agents of the present invention. In a specific embodiment, the anti-viral agent is an antibody which immunospecifically binds and neutralizes the hSARS virus or variants thereof, or any proteins derived from the virus.
therefrom. In another specific embodiment, the anti-viral agent is a polypeptide or nucleic acid molecule of the invention. The pharmaceutical compositions have utility as an anti-viral prophylactic agent and may be administered to a subject where the subject has been exposed or is expected to be exposed to a virus.

Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microspheres, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4422-4432). Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In a preferred embodiment, it may be desirable to introduce the pharmaceutical compositions of the invention into the lungs by any suitable route. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

In one embodiment, administration can be by direct injection at the site (or former site) infected tissues.

In another embodiment, the pharmaceutical composition can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.).


Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of an live attenuated, inactivated or killed hSARS virus, or recombinant or chimeric hSARS virus, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropanolamine, triethylamine, 2 ethylamino ethanol, histidine, procaine, etc.

The amount of the pharmaceutical composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of
the disease or disorder, and should be decided according to
the judgment of the practitioner and each patient’s circum-
cstances. However, suitable dosage ranges for intravenous
administration are generally about 20 500 micrograms of
active compound per kilogram body weight. Suitable dosage
ranges for intramuscular administration are generally about 0.01
pg/kg body weight to 1 mg/kg body weight. Effective doses
may be extrapolated from dose response curves derived from
in vitro or animal model test systems.

Suppositories generally contain active ingredient in the
range of 0.5% to 10% by weight; oral formulations preferably
contain 10% to 55% active ingredient.

The invention also provides a pharmaceutical pack or kit
comprising one or more containers filled with one or more
of the ingredients of the pharmaceutical compositions of
the invention. Optionally associated with such container(s)
can be a notice in the form prescribed by a governmental agency
regulating the manufacture, use or sale of pharmaceuticals or
biological products, which notice reflects approval by the
agency of manufacture, use or sale for human administration.
In a preferred embodiment, the kit contains an anti-viral agent
of the invention, e.g., an antibody specific for the polypep-
tides encoded by a nucleotide sequence of SEQ ID NO:1, 11,
13, 15, 2471 or 2473, or as shown in FIGS. 11 (SEQ ID
NOS: 17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS:
1100-1589, 1591-1964 and 1966-2470), or any hSARS epitope,
or a polypeptide or protein of the present invention, or a
nucleic acid molecule of the invention, alone or in combi-
nation with adjuvants, antivirals, antibiotics, analgesics,
bronchodilators, or other pharmaceutically acceptable
excipients.

The present invention further encompasses kits comprising
a container containing a pharmaceutical composition of the
present invention and instructions to use.

5.7 Detection Assays

The present invention provides a method for detecting an
antibody, which immunospecifically binds to the hSARS
virus, in a biological sample, for example blood, serum,
plasma, saliva, urine, etc., from a patient suffering from
SARS. In a specific embodiment, the method comprises
contacting the sample with the hSARS virus, for example,
of deposit no. CCTCC-V200303, or having a genomic nucleic
acid sequence of SEQ ID NO:15, directly immobilized on a
substrate and detecting the virus-bound antibody directly or
indirectly by a labeled heterologous anti-isotype antibody.
In another specific embodiment, the sample is contacted with
a host cell which is infected by the hSARS virus, for example,
of deposit no. CCTCC-V200303, or having a genomic
nucleic acid sequence of SEQ ID NO:15, and the bound
antibody can be detected by immunofluorescent assay as
described in Section 6.5, infra.

An exemplary method for detecting the presence or
absence of a polypeptide or nucleic acid of the invention in a
biological sample involves obtaining a biological sample
from various sources and contacting the sample with a com-
-pound or an agent capable of detecting an epitope or nucleic
acid (e.g., miRNA, genomic RNA) of the hSARS virus such
that the presence of the hSARS virus is detected in the
sample. A preferred agent for detecting hSARS mRNA or
genomic RNA of the invention is a labeled nucleic acid probe
capable of hybridizing to miRNA or genomic RNA encoding
a polypeptide of the invention. The nucleic acid probe can be,
for example, a nucleic acid molecule comprising or consist-
ing of the nucleotide sequence or SEQ ID NO:1, 11, 13, 15,
2471, or 2473, or a portion thereof, such as an oligonucleo-
etide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1,000 or more
contiguous nucleotides in length and sufficient to specifically
hybridize under stringent conditions to a hSARS mRNA or
genomic RNA.

In another preferred specific embodiment, the presence of
hSARS virus is detected in the sample by an reverse transcrip-
tion polymerase chain reaction (RT-PCR) using the primers
that are constructed based on a partial nucleotide sequence of
the genome of hSARS virus, for example, that of deposit
accession no. CCTCC-V200303, or having a genomic
nucleic acid sequence of SEQ ID NO:15, or based on a
nucleotide sequence of SEQ ID NO:1, 11, 13, 2471 or 2473.

In a non-limiting specific embodiment, preferred primers
to be used in a RT-PCR method are: 5’-TACACACCTCCAGC-
GTG-3’ (SEQ ID NO:3) and 5’-CAGGACGTCGAGAG-
AAAT-3’ (SEQ ID NO:4), in the presence of 2.5 mM MgCl2,
and the thermal cycles are, for example, but not limited to, 94°C
for 8 min followed by 40 cycles of 94°C for 1 min, 50°C for 1
min, 72°C for 1 min (also see Sections 6.7 and 6.8 infra).
In preferred embodiments, the primers comprise nucleic acid
sequence of SEQ ID NO:S2475 and 2476, or SEQ ID NO:
2480 and 2481. In preferred embodiments, the thermal cycles
are 94°C for 10 min followed by 40 cycles of 94°C for 30
seconds, 56°C for 30 seconds, 72°C for 30 seconds, 72°C
for 10 minutes. In preferred embodiments, the primers
comprise nucleic acid sequence of SEQ ID NO:S2477 and 2478.

In more preferred specific embodiment, the present invention
provides a real-time quantitative PCR assay to detect the
presence of hSARS virus in a biological sample by subjecting
the cDNA obtained by reverse transcription of the extracted
total RNA from the sample to PCR reactions using the
specific primers, such as those having nucleotide sequences of
SEQ ID NO:s 3 and 4, and a fluorescent dye, such as SYBR®
Green I, which fluoresces when bound non-specifically
to double-stranded DNA. The fluorescence signals from
these reactions are captured at the end of extension steps as
PCR product is generated over a range of the thermal cycles,
thereby allowing the quantitative determination of the viral
load in the sample based on an amplification plot (see Section
6.7, infra).

A preferred agent for detecting hSARS is an antibody that
specifically binds a polypeptide of the invention or any
hSARS epitope, preferably an antibody with a detectable
label. Antibodies can be polyclonal, or more preferably,
monoclonal. An intact antibody, or a fragment thereof (e.g.,
Fab or F(ab’)2) can be used.

The term “labeled”, with regard to the probe or antibody, is
intended to encompass direct labeling of the probe or anti-
obody by coupling (i.e., physically linking) a detectable sub-
stance to the probe or antibody, as well as indirect labeling of
the probe or antibody by reactivity with another reagent that
is directly labeled. Examples of indirect labeling include
detection of a primary antibody using a fluorescently labeled
secondary antibody and end-labeling of a DNA probe with
biotin such that it can be detected with fluorescently labeled
streptavidin. The detection method of the invention can be
used to detect mRNA, protein (or any epitope), or genomic
RNA in a sample in vitro as well as in vivo. For example, in
vitro techniques for detection of mRNA include northern
hybridizations, in situ hybridizations, RT-PCR, and RNase
protection. In vivo techniques for detection of an epitope of
hSARS include enzyme linked immunosorbent assays (ELI-
SAs), Western blots, immunoprecipitations and immuno-
fluorescence. In vitro techniques for detection of genomic RNA
include northern hybridizations, RT-PCT, and RNase
protection. Furthermore, in vivo techniques for detection of hSARS
include introducing into a subject organism a labeled anti-
obody directed against the polypeptide. For example, the anti-
In another embodiment, a cell is contacted with a test compound and infected with the hSARS virus. In certain embodiments, a control culture is infected with the hSARS virus in the absence of a test compound. The cell can be contacted with a test compound before, concurrently with, or subsequent to the infection with the hSARS virus. In a specific embodiment, the cell is a mammalian cell. In an even more specific embodiment, the cell is a human cell. In certain embodiments, the cell is incubated with the test compound for at least 1 minute, at least 5 minutes at least 15 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, at least 12 hours, or at least 1 day. The titer of the virus can be measured at any time during the assay. In certain embodiments, a time course of viral growth in the culture is determined. If the viral growth is inhibited or reduced in the presence of the test compound, the test compound is identified as being effective in inhibiting or reducing the growth or infection of the hSARS virus. In a specific embodiment, the compound that inhibits or reduces the growth of the hSARS virus is tested for its ability to inhibit or reduce the growth rate of other viruses to test its specificity for the hSARS virus.

In one embodiment, a test compound is administered to a model animal and the model animal is infected with the hSARS virus. In certain embodiments, a control model animal is infected with the hSARS virus without the administration of a test compound. The test compound can be administered before, concurrently with, or subsequent to the infection with the hSARS virus. In a specific embodiment, the model animal is a mammal. In an even more specific embodiment, the model animal can be, but is not limited to, a cotton rat, a mouse, or a monkey. The titer of the virus in the model animal can be measured at any time during the assay. In certain embodiments, a time course of viral growth in the culture is determined. If the viral growth is inhibited or reduced in the presence of the test compound, the test compound is identified as being effective in inhibiting or reducing the growth or infection of the hSARS virus. In a specific embodiment, the compound that inhibits or reduces the growth of the hSARS virus in the model animal is tested for its ability to inhibit or reduce the growth rate of other viruses to test its specificity for the hSARS virus.

6. EXAMPLES

The following examples illustrate the isolation and identification of the novel hSARS virus. These examples should not be construed as limiting.

Methods and Results


6.1 Clinical Subjects

The study included all 50 patients who fitted a modified World Health Organization (WHO) definition of SARS and were admitted to 2 acute regional hospitals in Hong Kong Special Administrative Region (HKSAR) between Feb. 26 to Mar. 26, 2003 (WHO. Severe acute respiratory syndrome (SARS) Weekly Epidemiol. Rec. 2003; 78: 81-83). A lung biopsy from an additional patient who had typical SARS and was admitted to a third hospital, was also included in the study. Briefly, the case definition for SARS was: (i) fever of 38°C or more; (ii) cough or shortness of breath; (iii) new pulmonary infiltrates on chest radiograph; and (iv) either a history of exposure to a patient with SARS or absence of response to empirical antimicrobial coverage for typical and atypical pneumonia (beta-lactams and macrolides, fluoroquinolones or tetracyclines).
Nasopharyngeal aspirates and serum samples were collected from all patients. Paired acute and convalescent sera and feces were available from some patients. Lung biopsy tissue from one patient was processed for a viral culture, RT-PCR, routine histopathological examination, and electron microscopy. Nasopharyngeal aspirates, feces and sera submitted for microbiological investigation of other diseases were included in the study under blinding and served as controls.

The medical records were reviewed retrospectively by the attending physicians and clinical microbiologists. Routine hematological, biochemical and microbiological examinations, including bacterial culture of blood and sputum, serological study and collection of nasopharyngeal aspirates for virological tests, were carried out.

6.2 Cell Line

FRHK-4 (fetal rhesus monkey kidney) cells were maintained in minimal essential medium (MEM) with 1% fetal calf serum, 1% streptomycin and penicillin, 0.2% nystatin and 0.05% gentamicin.

6.3 Viral Infection

Two-hundred µl of clinical (nasopharyngeal aspirates) samples, from two patients (see the Result section, infra), in virus transport medium were used to infect FRHK-4 cells. The inoculated cells were incubated at 37° C. for 1 hour. One ml of MEM containing 1 µg trypsin was then added to the culture and the infected cells were incubated in a 37° C. incubator supplied with 5% carbon dioxide. Cytopathic effects were observed in the infected cells after 2 to 4 days of incubation. The infected cells were passaged into new FRHK-4 cells and cytopathic effects were observed within 1 day after the inoculation. The infected cells were tested by an immunofluorescent assay for influenza A, influenza B, respiratory syncytial virus, parainfluenza types 1, 2 and 3, adenovirus and human metapneumovirus (hMPV) and negative results were obtained for all cases. The infected cells were also tested by RT-PCR for influenza A and human metapneumovirus with negative results.

6.4 Virus Morphology

The infected cells prepared as described above were harvested, pelleted by centrifugation and the cell pellets were processed for thin-section transmitted electron microscopic visualization. Viral particles were identified in the cells infected with both clinical specimens, but not in control cells which were not infected with the virus. Virions isolated from the infected cells were about 70-100 nanometers (FIG. 2). Viral capsids were found predominantly within the vesicles of the golgi and endoplasmic reticulum and were not free in the cytoplasm. Virus particles were also found at the cell membrane.

One virus isolate was ultracentrifuged and the cell pellet was negatively stained using phosphotungstic acid. Virus particles characteristic of Coronavirus were thus visualized. Since the human Coronavirus lổtherto recognized are not known to cause a similar disease, the present inventors postulated that the virus isolates represent a novel virus that infects humans.

6.5 Antibody Response to the Isolated Virus

To further confirm that this novel virus is responsible for causing SARS in the infected patients, blood serum samples from the patients who were suffering from SARS were obtained and a neutralization test was performed. Typically diluted serum (×50, ×200, ×800 and ×1600) was incubated with acetone-fixed FRHK-4 cells infected with hSARS at 37° C. for 45 minutes. The incubated cells were then washed with phosphate-buffered saline and stained with anti-human IgG-FITC conjugated antibody. The cells were then washed and examined under a fluorescent microscope. In these experiments, positive signals were found in 8 patients who had SARS (FIG. 3), indicating that these patients had an IgG antibody response to this novel human respiratory virus of Coronavirus. By contrast, no signal was detected in 4 negative-control paired sera. The serum titers of anti-hSARS antibodies of the tested patients are shown in Table 1.

Blinded samples:

| 1a  | Acute          | ≤50 |
| 1b  | Convalescent  | 1600|
| 2a  | Acute          | 50  |
| 2b  | Convalescent  | >1600|
| 3a  | Acute          | 50  |
| 3b  | Convalescent  | >1600|
| 4a  | Acute          | ≤50 |
| 4b  | Convalescent  | ≤50 |
| 5a  | Acute          | ≤50 |
| 5b  | Convalescent  | ≤50 |
| 6a  | Acute          | ≤50 |
| 6b  | Convalescent  | ≤50 |

NB: * patients with SARS

These results indicated that this novel member of Coronavirus is a key pathogen in SARS.

6.6 Sequences of the hSARS Virus

Total RNA from infected or uninfected FRHK-4 cells was harvested two days post-infection. One-hundred ng of purified RNA was reverse transcribed using Superscript II 10 reverse transcriptase (Invitrogen) in a 20 µl reaction mixture containing 10 µg of a degenerated primer (5'-GCCG-GAGCTCTGCAGAATTCCN13NNNNN-3', N=A, T, G or C; SEQ ID NO:5) as recommended by the manufacturer. Reverse transcribed products were then purified by a QIAquick PCR purification kit as instructed by the manufacturer and eluted in 30 µl of 10 mM Tris-HCl, pH 8.0. Three µl of purified cDNA products were add in a 25 µl reaction mixture containing 2.5 µl of 10xPCR buffer, 4 µl of 25 mM MgCl2, 0.5 µl of 10 mM dNTP, 0.25 µl of AmpliTaq Gold® DNA polymerase (Applied Biosystems), 2.5 µl of [α-32P] CTP (Amersham), 2 µl of 10 µM primer (5'-GCCG-GAGCTCTGCAGAATTCC-3'; SEQ ID NO:6). Reactions were thermal cycled through the following profile: 94°C for 8 min followed by 2 cycles of 94°C for 1 min, 40°C for 1 min, 72°C for 2 min. This temperature profile was followed by 35 cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 1 min. 6 µl of the PCR products were analyzed in a 5% denaturing polyacrylamide gel electrophoresis. Gel was exposed to X-ray film and the film was developed after an over-night exposure. Unique PCR products which were only identified in infected cell samples were isolated from the gel and eluted in a 50 µl of 1xTE buffer. Eluted PCR products were then re-amplified in 25 µl of reaction mixture containing
2.5 μl of 10x PCR buffer, 4 μl of 25 mM MgCl₂, 0.5 μl of 10 mM dNTP, 0.25 μl of AmpliTaq Gold DNA polymerase (Applied Biosystems), 1 μl of 10 μM primer (5'-CCGGAGC-GAGCTTGACGAAT-3' (SEQ ID NO:5)) and 5μl of 0.5 μM TaqGold primer (5'-CAAGACGTTGCAGCAAT-3' (SEQ ID NO:4)), which are constructed based on the presence of 2.5 mM MgCl₂ (94°C for 8 min followed by 40 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min). The summary of a typical RT-PCR protocol is as follows:

1. RNA Extraction
RNA from 140 μl of NPA samples is extracted by QiAquick viral RNA extraction kit and is eluted in 50 μl of elution buffer.

<table>
<thead>
<tr>
<th>RNA</th>
<th>11.5 μl</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1 M DTT</td>
<td>2 μl</td>
</tr>
<tr>
<td>5x buffer</td>
<td>4 μl</td>
</tr>
<tr>
<td>10 mM DNT</td>
<td>1 μl</td>
</tr>
<tr>
<td>Superscript II, 200 U/μl (Invitrogen)</td>
<td>1 μl</td>
</tr>
<tr>
<td>Random hexamer, 0.5 μg/μl</td>
<td>0.5 μl</td>
</tr>
<tr>
<td>Reaction condition:</td>
<td>42°C, 5 min</td>
</tr>
<tr>
<td>94°C, 3 min</td>
<td>4°C</td>
</tr>
</tbody>
</table>

2. PCR

| cDNA | 2 μl |
| 10 mM dNTP | 0.5 μl |
| 10x buffer | 5 μl |
| 25 mM MgCl₂ | 5 μl |
| 25 μM Forward primer | 0.5 μl |
| 25 μM Reverse primer | 0.5 μl |
| AmpliTaq Gold polymerase, 5 U/μl (Applied Biosystems) | 0.25 μl |
| Water | 36.25 μl |

Thermal-cycle condition: 95°C, 10 min, followed by 40 cycles of 95°C, 1 min; 50°C, 1 min; 72°C, 1 min.

3. PCR

cDNA generated by random primers is amplified in a 50 μl reaction as follows:

| cDNA | 2 μl |
| 10 mM dNTP | 0.5 μl |
| 10x buffer | 5 μl |
| 25 mM MgCl₂ | 5 μl |
| 25 μM Forward primer | 0.5 μl |
| 25 μM Reverse primer | 0.5 μl |
| AmpliTaq Gold polymerase, 5 U/μl (Applied Biosystems) | 0.25 μl |
| Water | 36.25 μl |

4. Primer Sequences

Primers were designed based on the RNA-dependent RNA polymerase encoding sequence (SEQ ID NO:1) of the hSARS virus.

**Forward primer:** 5' TACACACCTCAGGGTGG 3' (SEQ ID NO:3)

**Reverse primer:** 5' CAGCGACGTTGCAGCAAT 3' (SEQ ID NO:4)

Product size: 182 bps

Real-Time Quantitative PCR Assay

Total RNA from 140 μl of nasopharyngeal aspirate (NPA) was extracted by QiAamp® virus RNA mini kit (Qiagen) as instructed by the manufacturer. Ten μl of diluted RNA samples were reverse transcribed by 200 U of Superscript III reverse transcriptase (Invitrogen) in a 20 μl reaction mixture containing 0.15 μg of random hexamers, 10 mM dTTP, and 0.5 mM dNTP, as instructed. Complementary DNA was then amplified in a SYBR® Green fluorescence reaction (Roche) mixtures. Briefly, 20 μl reaction mixtures containing 2 μl of cDNA, 3.5 mM MgCl₂, 0.25 μM of forward primer (5’-TACACACCTCAGGGTGG-3’; SEQ ID NO:3) and 0.25 μM of reverse primer (5’-CAGCGACGTTGCAGCAAT-3’; SEQ ID NO:4) were thermal-cycled by a Light-Cycler (Roche) with the PCR program: 95°C, 10 min followed by 50 cycles of 95°C, 10 min; 57°C, 5 sec; 72°C, 9 sec. Plasmids containing the target sequence were used as positive controls. Fluorescence signals from these reactions were cap-
tured at the end of extension step in each cycle. To determine the specificity of the assay, PCR products (184 base pairs) were subjected to a melting curve analysis at the end of the assay (65°C to 95°C, 0.1°C C, per second).

6.8 Detection of N-ssRNA Virus in Patients
6.8.1 RT-PCR Diagnosis Protocol for Coronavirus in SARS Patients

Equipment required (for 96 samples):
1×SV Total RNA Isolation system
2×Mega titer plate
5×96-well PCR plate
1×5-10 μl multi-channel pipette
1×10-100 μl multi-channel pipette
1×20-200 μl multi-channel pipette
1×vacuum pump
1×tongue and bucket rotator with microtiter plate buckets
2×PCR machine (96-well plate compatible)
1×Gel electrophoresis apparatus

Station 1—Clinical Samples Handling (1 Medical Officer/ Clinical Technician)

Alloqut 500 μl sample in viral transport medium (containing, per liter, 2 g of sodium bicarbonate, 5 g of bovine serum albumin, 200 μg of vancomycin, 18 μg of amikacin, and 160 U of nystatin in Earle's balanced salt solution) from each individual vial into a well of 96-well mega titer plate containing 500 μl lysis buffer (1×) containing 100 μl PK-15 cell (ATCC CCL-33; 5.0×10^5 cell/ ml) in complete minimum essential medium with Earle's salt (EMEM, Invitrogen) as internal control.**

*Station 1 should be carried out inside Class III biological safety cabinet.
**At least one negative sample should be included as a control.

Mix the lysate by pipetting up-and-down 3 times
Proceed to Station 2.

Station 2—Total RNA Extraction (1 Laboratory Technician)

Set up the Vacuum Manifold unit. Place the binding plate onto the manifold Base.

Transfer the lysate from mega titer plate to each well of the SV 96 Binding Plate (binding plate).

Apply vacuum until the lysate passes through the binding plate. Release vacuum.

Add 500 μl of SV RNA Wash Solution (wash solution) to each well of binding plate.

Apply vacuum until the wash solution passes through binding plate. Release vacuum.

Prepare DNase incubation mix for an entire 96-well plate as below:

<table>
<thead>
<tr>
<th>Yellow Core Buffer</th>
<th>2 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.9% NaCl</td>
<td>250 μl</td>
</tr>
<tr>
<td>DNase I</td>
<td>250 μl</td>
</tr>
</tbody>
</table>

Apply 25 μl freshly prepared DNase incubation mix directly to the membrane of the binding plate.
Incubate at 20-25°C for 10 minutes.
Add 200 μl of SV DNase Stop Solution to each well of the binding plate.
Apply vacuum until the SV DNase Stop Solution passes through the binding plate. Release vacuum.

Add 500 μl wash solution to each well of the binding plate. Apply vacuum until wash solution passes through the binding plate. Turn off vacuum.
Spin the binding plate at 3000×g for 30 seconds to remove residue wash solution.
Transfer the binding plate to top of a 96-well RT plate.

Add 50 μl nuclease-free water into each well of the binding plate to elute RNA.
Incubate at room temperature for 1 minute.
Spin the binding plate at 3000×g, 4°C, for 1 minute.
Collect eluted RNA in the 96-well RT plate.
Add 5 μl of 3 M sodium acetate and 200 μl of 95% ethanol into each well of the plate.
Place the RT plate on ice and incubate for 15 minutes.
Spin the plate at 3000×g, 4°C, 15 minutes.
Discard supernatant by inverting the plate and blotting on a clean paper towel.
Wash the pellet with 200 μl of 70% ethanol.
Spin the plate at 3000×g, 4°C, 10 minutes.
Discard supernatant by inverting the plate and blotting on a clean paper towel.
Air-dry the pellet for 5 minutes.
Add 12 μl of nuclease-free water into each well.
Vortex the plate briefly to dissolve the pellet (for an example result, see FIG. 18).
Proceed to Station 3.

Station 3—Reverse Transcription (1 Laboratory Technician)
Prepare RT master mix for an entire 96-well plate in a 1.5-ml tube as below (100 reactions):

<table>
<thead>
<tr>
<th>Per Reaction</th>
<th>×100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random hexamers, 3 μg/μl</td>
<td>0.05 μl</td>
</tr>
<tr>
<td>DNTPs, 10 mM</td>
<td>1 μl</td>
</tr>
<tr>
<td>First-strand buffer, 5×</td>
<td>4 μl</td>
</tr>
<tr>
<td>DTT, 0.1 M</td>
<td>2 μl</td>
</tr>
<tr>
<td>Superscript II, 200 U/μl</td>
<td>1 μl</td>
</tr>
<tr>
<td>Total</td>
<td>8.05 μl</td>
</tr>
</tbody>
</table>

Aliquot 100 μl RT mix into 8 wells of a clean 96-well master mix plate.
From this plate, transfer 8.05 μl RT mix to each well of RT plate containing 12 μl RNA mix by pipetting up-and-down for 3 times with a multi-channel pipette. REPLACE TIP AFTER EACH TRANSFER.
Incubate the samples at 42°C for 50 minutes followed by 70°C for 15 minutes.
Proceed to Station 4.

Station 4—N-ssRNA Specific PCR (1 Laboratory Technician)
Prepare PCR master mix for an entire 96-well plate in two 2059 culture tubes as below (100 reactions):

<table>
<thead>
<tr>
<th>N-specific PCR</th>
<th>Control PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per 25 μl Reaction</td>
<td>×100</td>
</tr>
<tr>
<td>mQH2O</td>
<td>18.65 μl</td>
</tr>
<tr>
<td>10× PCR buffer</td>
<td>2.5 μl</td>
</tr>
<tr>
<td>25 mM MgCl2</td>
<td>1.5 μl</td>
</tr>
<tr>
<td>10 mM dNTPs</td>
<td>0.25 μl</td>
</tr>
<tr>
<td>Forward primer</td>
<td>0.5 μl</td>
</tr>
<tr>
<td>Reverse primer</td>
<td>0.5 μl</td>
</tr>
<tr>
<td>10× Taq</td>
<td>0.1 μl</td>
</tr>
<tr>
<td>Template DNA</td>
<td>1 μl</td>
</tr>
<tr>
<td>Total</td>
<td>25 μl</td>
</tr>
</tbody>
</table>
N-gene specific PCR and control PCR are performed in two individual PCR plates. Aliquot 200 μl PCR master mix into the first column of a 96-well PCR plate. From the first column, aliquot 24 μl of master mix into each well of PCR plate. Transfer 1 μl of cDNA template (from station 4) into each well of PCR plate. Mix by pipetting up-and-down for 3 times with a multi-channel pipette. REPLACE TIP AFTER EACH TRANSFER. Seal the plate with sealing tape. Perform the following reaction in two 96-well PCR machines:

<table>
<thead>
<tr>
<th>N-gene specific PCR</th>
<th>Control PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>94°C 10 minutes</td>
<td>94°C 10 minutes</td>
</tr>
<tr>
<td>94°C 30 seconds</td>
<td>94°C 30 seconds</td>
</tr>
<tr>
<td>55°C 30 seconds</td>
<td>55°C 30 seconds</td>
</tr>
<tr>
<td>72°C 30 seconds</td>
<td>72°C 45 seconds</td>
</tr>
<tr>
<td>72°C 10 minutes</td>
<td>72°C 10 minutes</td>
</tr>
</tbody>
</table>

40 cycles 35 cycles

Station 5—Gel Electrophoresis (1 Laboratory Technician)
Mix 5 μl of N-gene specific PCR product and 5 μl control PCR product with 1 μl bromophenol blue loading dye. Load the samples into the wells of a 2% agarose gel. Electrophoresize the PCR products at 140V, 250 mA for 30 minutes. Stain the gel with ethidium bromide. Visualize the gel with UV and record the result. 6.8.2 Using Primers of SEQ ID Nos:2480 and 2481 RT-PCR diagnostic protocol was performed as described in Section 6.8.1 with some modifications.

RNA Isolation from Clinical Samples
Clinical samples including nasopharyngeal aspirates (NPA) and stool specimens were provided by the Department of Microbiology, The University of Hong Kong. In addition, tracheal dispersion and lung biopsy from an index patient A described in New Engl. J Med. 348:1967-76 (by Drosten C. S., et al., 2003) at three time points was also collected. Sample collection was conducted from Apr. 1 to Apr. 28, 2003 in local hospitals. Method of sample collection was described in the previous section (also see, Poon et al., 2003, Clinical Chemistry 49:953-955). Total RNA extraction from clinical samples was carried out with SV96 Total RNA Isolation System (Promega, Wis., USA), with following modifications from manufacturer’s protocol. Five-hundred (500) μl of NPA/ stool sample in viral transport medium (containing, per liter, 2 g of sodium bicarbonate, 5 g of bovine serum albumin, 200 μg of vancomycin, 18 μg of amikacin, and 160 U of nystatin in Earle’s balanced salt solution) was mixed with equal volume of SV RNA lysis Buffer containing 100 μl of pig kidney epithelial (PK-15) cell (ATCC CCL-33; 5.0 x 10^6 cells/ml) in complete minimal essential medium with Earle’s salt (EMEM, Invitrogen) as internal control. The mixture was transferred to the wells of the SV 96 Binding Plate. After washing with 500 μl of SV RNA Wash Solution prior to elution step, the plate was spun at 3000xg for 30 seconds to remove residue wash solution. RNA was then eluted with 50 μl of nuclease-free water, and was collected in a clean 96-well PCR plate by spinning the plate at 3000xg for 1 minute. Eluted RNA was then concentrated by incubating on ice for 15 minutes, in the presence of 5 μl of 3 M sodium acetate and 200 μl of 95% ethanol. After centrifugation at 3000xg, 4°C, for 15 minutes, RNA pellet was washed with 200 μl of 75% ethanol and dissolved with 12 μl of nuclelease-free water. Extracted RNA was immediately reverse-transcribed to first-strand cDNA.

First-Strand cDNA Synthesis
Reverse-transcription was performed with 200 U of SuperScript II reverse transcriptase (Invitrogen, USA) in a 20 μl reaction containing 0.15 μg of random hexamers, RT buffer (1x), 10 mM dithiothreitol (DTT) and 0.5 mM deoxyribonucleotide triphosphates (dNTPs). Reaction was carried out in Peltier Thermal Cycler (MJ Research) with the following conditions: 50 minutes at 42°C, followed by 15 minutes at 70°C.

Polymerase Chain Reaction (PCR)
Primers were designed according to complete SARS CoV genomic sequence of a local specimen HK-39 announced previously (accession no. AY278491). Forward primer (SRS251): 5’-GCAGTCAACCCCTTTCGGC-3′; SEQ ID NO:2480, corresponding to nt 28658-28676 of HK-39 SARS genome, i.e., CACCCTCC00503) and reverse primer (SRS252): 5’-GCCTACGACGAGCATTTC-3′; SEQ ID NO:2481; corresponding to nt 28866-28883 of HK-39 SARS genome amplified a 225 bp fragment from the region of N-gene that showed no homology to other coronavirus. Primers amplifying RNA-dependent RNA polymerase (1b gene) were used as parallel control (coro3: 5’-TACACACTTCAACGGTGG-3′ (SEQ ID NO:3), corresponding to nt 18041-18057; and coro4: 5’-CAGCAGGTCGACAAAT-3′ (SEQ ID NO:4), corresponding to nt 18207-18222. Department of Microbiology, the University of Hong Kong). Both ampiclons were cloned into plasmid (pCR2.1 cloning vector (FIG. 17). Serially diluted plasmid was then used to determine the dynamic range and optimal condition of the PCR (FIGS. 21A and 21B). Another set of primer that amplifying a 745 bp fragment from pig β-actin gene was employed as an internal control for the diagnostic PCR assay (actin-F: 5’-TGAGACCTTCAACAGCGCC-3′(SEQ ID NO:2482); and actin-R: 5’-ATGCTGGGAAAGCTTGAC-3′ (SEQ ID NO:2483)).

Conventional PCR and gel electrophoresis was carried out as preliminary experiment. Briefly, 1 μl of cDNA from clinical samples was amplified with 0.5 U Taq DNA polymerase recombinant (Invitrogen Life Technologies) in a 25-μl reaction containing PCR buffer (1x), 1.5 mM MgCl₂, 0.1 mM dNTPs and 0.5 pmol of each forward and reverse primers. Reaction was performed in Peltier Thermal Cycler (MJ Research) with the following conditions: 3 minutes at 94°C, followed by 50 cycles of 94°C for 10 seconds, 56°C for 10 seconds, 72°C for 15 seconds, and a 10-minute final extension step at 72°C. Amplicons were analyzed with 2% agarose gel electrophoresis (FIG. 23). Quantitative real-time PCR using SYBR® SYBR® green fluorophore was performed in diagnosis of clinical samples. In a 25 μl reaction, 1 μl cDNA template was mixed with 12.5 μl (2x) Green PCR Master Mix (Applied Biosystems) and 0.5 pmol of each forward and reverse primer. Volume of the reaction was adjusted to 25 μl with distilled water. Reactions were performed in iCycler iQ Real-Time PCR Detection System (Bio-Rad) under the same condition as the conventional PCR. Fluorescence signals (GAM, excitation–400 nm, emission–530 nm) were collected at the end of each extension step during the PCR cycles (FIG. 22A). Threshold cycle (Ct) of each sample was determined using maximum curvature approach. Melting curve analysis was performed after 10 minutes final extension (FIG. 22B). cDNA from non-SARS patients, including patients suffering from adenovirus (n=5), respiratory syncytial virus (n=5), human metapneumovirus (n=5), influenza A virus
(n=5), or influenza B virus (n=5) infection, were used as negative controls for the assay.

Northern Blot Analysis
SARS-CoV HK-39 strain infected Vero cell was provided by Department of Microbiology, the University of Hong Kong. Total RNA was extracted from the cell with TRIzol® reagent (Invitrogen Life Technologies) according to the manufacturer’s protocol. Eight (8) µg of total RNA was separated by electrophoresis on a 1% agarose gel containing 3.7% formaldehyde. RNA was transferred to a positively charged nylon membrane (Roche Diagnostics Corporation) by capillary blotting and fixed by UV cross-linking. cDNA synthesized with the same RNA sample was used as template for probe synthesis. Four pairs of primers amplifying fragments from 1b (nt 18057-18222; SEQ ID NO:2484), S (nt 21920-22107; SEQ ID NO:2485), M (nt 26867-26996; SEQ ID NO:2486) and N (nt 28658-28883; SEQ ID NO:2487) gene were used in probe synthesis. DIG-labeling of probes, hybridization and detection of bands were performed with the digoxigenin system according to the manufacturer’s procedures (Roche Molecular Biochemicals). Signals were then analysed with chemiluminescence (FIG. 24).

Results and Discussion
A large-scale RT-PCR assay provides a rapid means in monitoring and screening of SARS suspects. The result can be used to complement clinical diagnostic evaluation. In order to achieve a diagnostic purpose, the assay should be reliable and its accuracy should be assured so as to prevent occurrence of false negative and false positive results. However, accuracy of the test may be influenced by several factors. A common technical problem with PCR is a failure of amplification due to the presence of PCR inhibitors (see FIG. 21).

These PCR inhibitors included hem compounds found in blood, aqueous and vitreous humors, heparin, EDTA, urine and polyamines (Fredricks et al., 1998, J. Clin. Micro. 36:2810-16). Currently, NPA or stool samples were collected into transport medium to maintain the viability of the viral particles. RT-PCR was inhibited when total RNA extracted was used directly for first-strand cDNA synthesis without any treatment (25 out of 27 samples) in preliminary experiment. However, after a simple ethanol precipitation step, the amplification of RNA could be retained (FIG. 19). Same result was obtained by either using SV or SV96 total RNA Isolation System (data not shown). It demonstrated that some components either in the medium or NPA/stool samples would affect the downstream processes of the diagnosis test.

In addition, current sample collection procedure dilutes the virus titer in the samples, especially during early stage of infection, in which the virus titer is low in nasal and throat swab specimens (Drosten et al., 2003, New England Journal of Medicine, on-line at http://content.nejm.org/cgi/reprint/NEJM00030747v2). It was suggested that the sensitivity of PCR tests for SARS depended on the quality of the specimen and the time of testing during the course of the illness. In order to increase sensitivity of the test, total RNA isolated from clinical samples was concentrated prior to 1st strand cDNA synthesis.

In order to avoid false negative PCR results due to failure in the process of RNA isolation and 1st strand cDNA synthesis, total RNA was extracted from clinical samples in parallel with PK-15 mammalian cells. FIG. 23 showed the RT-PCR screening result on 48 clinical samples, including both NPA and stool samples. Diagnostic PCR was performed in parallel with β-actin PCR. All samples were positive in β-actin PCR. The result indicated that RNA and cDNA could be extracted and synthesized successfully from the samples in a single-step protocol as disclosed herein. With this internal control, total RNA isolation and cDNA synthesis from the samples were ensured, which eliminated false negative that resulted from failure in either one of the above processes. Moreover, 96-well assay format currently developed can be adopted into a high-throughput screening protocol, with which we are able to obtain diagnostic result of more than 90 clinical samples in 3 hours with 1 clinical personnel, while the current existing protocol, in which samples are processed in individual tubes, can only handle about 30-50 samples a day per technician.

Real-time quantitative PCR assay is more sensitive than conventional agarose gel-electrophoresis-associated PCR assay (Poon et al., J. Clin. Virol. 28:233-8) and therefore employed for SARS-CoV diagnosis purpose. Positive signals were detected in 38 of 136 randomly selected clinical samples in both N-gene and 1b-gene specific PCR. Among these cases, 3 positive samples and 2 were stool samples (2.2%) and 35 were NPA samples (25.7%). Detection rate of the assay employing N-gene specific RT-PCR at different time points was shown in Table 2.

TABLE 2

<table>
<thead>
<tr>
<th>Date of onset</th>
<th>No. of sample</th>
<th>No. of positive</th>
<th>Detection rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2</td>
<td>15</td>
<td>2</td>
<td>13.3</td>
</tr>
<tr>
<td>3-4</td>
<td>17</td>
<td>4</td>
<td>23.5</td>
</tr>
<tr>
<td>5-6</td>
<td>15</td>
<td>4</td>
<td>26.7</td>
</tr>
<tr>
<td>7-8</td>
<td>13</td>
<td>5</td>
<td>38.5</td>
</tr>
<tr>
<td>9-10</td>
<td>9</td>
<td>4</td>
<td>44.4</td>
</tr>
<tr>
<td>Negative control</td>
<td>19</td>
<td>All negative</td>
<td></td>
</tr>
</tbody>
</table>

Affirmative of these 38 positive cases was confirmed by melting curve analysis of PCR products. Specific melting temperature of N gene and 1b gene PCR products (85.5°C and 80.5°C, respectively) indicated that the target fragments were amplified in the reaction. Specificity of the assay was also validated with non-SARS patients samples, including patients suffering from adenovirus (n=5), respiratory syncytial virus (n=5), human metapneumovirus (n=5), influenza A virus (n=5) and influenza B virus (n=5). The result shows that all of these samples were negative in the assay (FIG. ??). These results indicate that the N-gene specific RT-PCR assay is specific for SARS-CoV diagnosis.

Furthermore, we also demonstrated that the N-gene specific PCR was more sensitive than that of PCR amplifying 1b RNA polymerase gene. Amplification conditions for both PCR assays were optimized (see FIG. 22) first with the plasmid construct containing 1:1 ratio of 1b- and N-gene fragment (see FIG. 20). Dynamic range of N-gene specific PCR was obtained (FIG. ??) and it was found to be lower Ct values than that of 1b-specific PCR. This revealed that N-gene specific PCR could achieve higher amplification efficiency than 1b-gene specific PCR when using same copy number of template. PCR with cDNA from clinical samples or virus infected Vero cells were then performed. FIG. 22A shows the Ct and half-maximal values of the fluorescent signal of N gene and 1b gene specific PCR generated from NPA, true heald dispersion and lung biopsy from patient A. The results indicated that fluorescent signals given in N gene specific PCR are higher (26.0% in average, ranged from 6.3-60%) than that of 1b specific PCR in all positive samples. Furthermore, Ct values of N gene specific PCR are lower (0.1-4.6 cycles) than that of 1b specific PCR among most of the SARS-CoV positive samples (Table 3).
Statistical analysis indicates that Ct of N-gene PCR assay is significantly lower than that of ab-gene assay (95% confidence interval=0.74 to 2.23, F-test). Stronger fluorescence signals and lower Ct values of N gene specific PCR provide a more sensitive diagnostic result and much target for the assay.

Using cDNA from SARS-CoV infected Vero cells, amplification curves shown in FIG. 21B show the differences between N gene and 1b gene specific PCR. Ct of the N gene and 1b gene specific PCR was 35.3 and 37.8, respectively. This phenomenon had two main causes: (1) Expression level of N gene was higher than that of 1b gene; and (2) Copy number of N gene was much larger than that of 1b gene because each transcript preceded a copy of N gene, in SARS-CoV infected cells. Northern blot analysis supported this hypothesis (FIG. 24). When N-gene specific PCR product was used as a probe, at least five transcriptions from the virus were hybridized and gave positive signals (FIG. 24). This result agreed with the findings in which five subgenomic mRNAs were detected by Northern hybridization of RNA from SARS-CoV infected cells using a probe derived from the 3' untranslated region (Rota et al., 2003, Science 300: 1394-99). On the other hand, when 1b PCR product was used as a probe, only two transcripts with high molecular size were hybridized, demonstrating that the copy number of N gene was much higher than that of 1b gene, during transcription and gene expression in the host cells. The Northern hybridization result strongly supports the conclusion that PCR amplifying regions in N gene of the SARS-CoV are more sensitive than other regions as a target for diagnostic screening. It is possible that amplification of more than one genome region may increase the specificity of the test (Yam W. C., et al., 2003, J. Clin. Microbiol. 41:4521-24).

In conclusion, we have developed a new generation of RT-PCR diagnosis test which is more sensitive than conventional diagnostic test for the detection of the coronavirus associated with SARS. The assay provides a high throughput, highly sensitive screening platform, which enables us to scale up to test hundreds of thousands of suspected SARS cases under one single working line. Incorporation of PIK15 cell as an internal control in the assay and use of N gene as a diagnosis locus in addition to 1b gene can enhance the sensitivity and accuracy of the test. We are adapting the protocol to 96-well real-time quantitative PCR and sequencing format to shorten the time required for the test and to obtain information on genotypic variation of the virus.

Clinical Results:
Clinical Findings:
All 50 patients with SARS were ethnic Chinese. They represented 5 different epidemiologically linked clusters as well as additional sporadic cases fitting the case definition.

They were hospitalized at a mean of 5 days after the onset of symptoms. The median age was 42 years (range of 23 to 74) and the female to male ratio was 1.3. Fourteen (28%) were health care workers and five (10%) had a history of visit to a hospital experiencing a major outbreak of SARS. Thirteen (26%) patients had household contacts and 12 (24%) others had social contacts with patients with SARS. Four (8%) had a history of recent travel to mainland China.

The major complaints from most patients were fever (90%) and shortness of breath. Cough and myalgia were present in more than half the patients (Table 4). Upper respiratory tract symptoms such as rhinorrhea (24%) and sore throat (20%) were present in a minority of patients. Diarrhea (10%) and anorexia (10%) were also reported. At initial examination, auscultatory findings, such as crepitations and decreased air entry, were present in only 38% of patients. Dry cough was reported by 62% of patients. All patients had radiological evidence of consolidation, at the time of admission, involving 1 zone (in 36), 2 zones (13) and 3 zones (1).

<table>
<thead>
<tr>
<th>Clinical symptoms</th>
<th>Number (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>50 (100%)</td>
</tr>
<tr>
<td>Chills or rigors</td>
<td>37 (74%)</td>
</tr>
<tr>
<td>Cough</td>
<td>31 (62%)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>27 (54%)</td>
</tr>
<tr>
<td>Malaise</td>
<td>25 (50%)</td>
</tr>
<tr>
<td>Running nose</td>
<td>12 (24%)</td>
</tr>
<tr>
<td>Sore throat</td>
<td>10 (20%)</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>10 (20%)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>10 (20%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (10%)</td>
</tr>
<tr>
<td>Headache</td>
<td>10 (20%)</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>6 (12%)</td>
</tr>
</tbody>
</table>

Truncal maculopapular rash was noted in 1 patient.

In spite of the high fever, most patients (98%) had no evidence of a leukocytosis. Lymphopenia (68%), leucopenia (26%), thrombocytopenia (40%) and anemia (18%) were present in peripheral blood examination (Table 5). Parenchymal liver enzyme, alanine aminotransferase (ALT) and muscle enzyme, creatinine kinase (CPK) were elevated in 34% and 26% respectively.

<table>
<thead>
<tr>
<th>Laboratory parameter</th>
<th>Mean (range)</th>
<th>Percentage of abnormal</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin</td>
<td>12.9 (8.9-15.9)</td>
<td>11.5-16.5 g/dl</td>
<td></td>
</tr>
<tr>
<td>Anaemia</td>
<td>9 (18%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Routine microbiological investigations for known viruses and bacteria by culture, antigen detection, and PCR were negative in most cases. Blood culture was positive for *Escherichia coli* in a 74-year-old male patient, who was admitted to intensive care unit, and was attributed to hospital acquired urinary tract infection. *Klebsiella pneumoniae* and *Hemophilus influenzae* were isolated from the sputum specimens of 2 other patients on admission.

Oral levofloxacin 500 mg q24 h was given in 9 patients and intravenous (1.2 g q8 h) oral (375 mg tid) amoxicillin-clavulanate and intravenous oral clarithromycin 500 mg q12 h were given in another 40 patients. Four patients were given oral oseltamivir 75 mg bid. In one patient, intravenous ceftriaxone 2 gm q24 h, oral azithromycin 500 mg q24 h, and oral amantadine 100 mg bid were given for empirical coverage of typical and atypical pneumonia.

Nineteen patients progressed to severe disease with oxygen desaturation and were required intensive care and ventilatory support. The mean number of days of deterioration from the onset of symptoms was 8.3 days. Intravenous ribavirin 8 mg/kg q8 h and steroid was given in 49 patients at a mean day of 6.7 after onset of symptoms.

The risk factors associated with severe complicated disease requiring intensive care and ventilatory support were older age, lymphopenia, impaired ALT, and delayed initiation of ribavirin and steroid (Table 6). All the complicated cases were treated with ribavirin and steroid after admission to the intensive care unit whereas all the uncomplicated cases were started on ribavirin and steroid in the general ward. As expected, 31 uncomplicated cases recovered or improved whereas 8 complicated cases deteriorated with one death at the time of writing. All 50 patients were monitored for a mean of 12 days at the time of writing.

### TABLE 6

<table>
<thead>
<tr>
<th>Laboratory parameter</th>
<th>Mean (range)</th>
<th>Percentage of abnormal</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>White cell count</td>
<td>5.17 (1.1-11.4)</td>
<td>13 (26%)</td>
<td>4.1-11 x 10^9/L</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>0.78 (0.3-1.5)</td>
<td>34 (68%)</td>
<td>1.5-4.0 x 10^9/L</td>
</tr>
<tr>
<td>Platelet count</td>
<td>53.6 (25-65)</td>
<td></td>
<td>150-400 x 10^9/L</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>174 (88-351)</td>
<td>20 (4%)</td>
<td>6-53 U/L</td>
</tr>
<tr>
<td>Elevation ALT</td>
<td>63 (11-350)</td>
<td>17 (34%)</td>
<td>20-60 U/L</td>
</tr>
<tr>
<td>Albumin</td>
<td>37 (26-50)</td>
<td>34 (68%)</td>
<td>42-54 g/L</td>
</tr>
<tr>
<td>Low albumin</td>
<td>33 (21-42)</td>
<td>24-36 g/L</td>
<td></td>
</tr>
<tr>
<td>Elevated globulin</td>
<td>44 (13-179)</td>
<td>10 (20%)</td>
<td></td>
</tr>
<tr>
<td>Creatinine kinase</td>
<td>544 (31-1379)</td>
<td>13 (26%)</td>
<td></td>
</tr>
<tr>
<td>Elevated creatinine</td>
<td>544 (31-1379)</td>
<td>13 (26%)</td>
<td></td>
</tr>
</tbody>
</table>

**Complicated case (n = 19)**

**Uncomplicated case (n = 31)**

### TABLE 6-continued

<table>
<thead>
<tr>
<th>Complicated case (n = 19)</th>
<th>Uncomplicated case (n = 31)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age (range)</td>
<td>40.5 ± 12.7</td>
<td>39.0 ± 10.7</td>
</tr>
<tr>
<td>Male/Female ratio</td>
<td>8/14</td>
<td>14/17</td>
</tr>
<tr>
<td>Underlying illness</td>
<td>5/1</td>
<td>1/1</td>
</tr>
<tr>
<td>Mode of contact</td>
<td>Travel to China</td>
<td>Health care worker</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>9</td>
</tr>
</tbody>
</table>
nasopharyngeal aspirate, lung biopsy and post-mortem lung. He had a significant rise in titer of antibodies against his own hSARS isolate from 1/200 to 1/1600.

The second patient from whom a hSARS Virus was isolated, was a 42-year-old female with good past health. She had a history of travel to Guangzhou in mainland China for 2 days. She presented with fever and diarrhea 5 days after her return to Hong Kong. Physical examination showed crepitation over the right lower zone which had a corresponding alveolar shadow on the chest radiograph. Investigation revealed leukocytosis (2.7×10⁹/L), lymphopenia (0.6×10⁹/L), and thrombocytopenia (104×10⁹/L). Despite the empirical antimicrobial coverage with amoxicillin-clavulanate, clarithromycin, and oseltamivir, she deteriorated 5 days after admission and required mechanical ventilation and intensive care for 5 days. She gradually improved without receiving treatment with ribavirin or steroid. Her nasopharyngeal aspirate was positive for the virus in the RT-PCR and she was seroconverted from antibody titre <1/50 to 1/1600 against the hSARS isolate.

**Virological Findings:**

Viruses were isolated on FRhK-4 cells from the lung biopsy and nasopharyngeal aspirate, respectively, of two patients described above. The initial cytopathic effect appeared between 2 and 4 days after inoculation, but on subsequent passage, cytopathic effect appeared in 24 hours. Both virus isolates did not react with the routine panel of reagents used to identify virus isolates including those for influenza A, B parainfluenza types 1,2,3, adenovirus and respiratory syncytial virus (DAKO, Glostrup, Denmark). They also failed to react in RT-PCR assays for influenza A and HMPV or in PCR assays for mycoplasma. The virus was ether sensitive, indicating that it was an enveloped virus. Electron microscopy of negatively stained (2% potassium phospho-tungstate, pH 7.0) cell culture extracts obtained by ultracentrifugation showed the presence of pleomorphic enveloped viral particles, of about 80-90 nm (ranging 70-130 nm) in diameter, whose surface morphology appeared comparable to members of Coronaviridae (FIG. 5a). Thin section electron microscopy of infected cells revealed virus particles of 55-90 nm diameter within the smooth-walled vesicles in the cytoplasm (FIG. 5b). Virus particles were also seen at the cell surface. The overall findings were compatible with infections in the cells caused by viruses of Coronaviridae.

A thin section electron micrograph of the lung biopsy of the 53 year old male contained 60-90-nm viral particles in the cytoplasm of desquamated cells. These viral particles were similar in size and morphology to those observed in the cell-cultured virus isolate from both patients (FIG. 4).

The RT-PCR products generated in a random primer RT-PCR assay were analyzed and unique bands found in the virus infected specimen was cloned and sequenced. Of 30 clones examined, a clone containing 646 base pairs (SEQ ID NO:1) of unknown origin was identified. Sequence analysis of this DNA fragment suggested this sequence had a weak homology to viruses of the family of Coronaviridae (data not shown). Deduced amino acid sequence (215 amino acids: SEQ ID NO:2) from this unknown sequence, however, had the highest homology (57%) to the RNA polymerase of bovine coronavirus and murine reovirus, confirming that this virus belongs to the family of Coronaviridae. Phylogenetic analysis of the protein sequences showed that this virus, though most closely related to the group II coronaviruses, was a distinct virus (FIGS. 5a and 5b).

Based on the 646 bp sequence of the isolate, specific primers for detecting the new virus was designed for RT-PCR detection of this hSARS virus genome in clinical specimens. Of the 44 nasopharyngeal specimens available from the 50 SARS patients, 22 had evidence of hSARS RNA. Viral RNA was detectable in 10 of 18 fecal samples tested. The specificity of the RT-PCR reaction was confirmed by sequencing selected positive RT-PCR amplified products. None of 40 nasopharyngeal and fecal specimens from patients with unrelated diseases were reactive in the RT-PCR assay.

To determine the dynamic range of real-time quantitative PCR, serial dilutions of plasmid DNA containing the target sequence were made and subjected to the real-time quantitative PCR assay. As shown in FIG. 7a, the assay was able to detect as little as 10 copies of the target sequence. By contrast, no signal was observed in the water control (FIG. 7a). Positive signals were observed in 23 out of 29 serologically confirmed SARS patients. In all of these positive cases, a unique PCR product (Tm=82° C) corresponds to the signal from the positive control was observed (FIG. 7b, and data not shown). These results indicated this assay is highly specific to the target. The copy numbers of the target sequence in these reactions range from 4539 to less than 10. Thus, as high as 6.48×10⁵ copies of this viral sequence could be found in 1 ml of NPA sample. In 5 of the above positive cases, it was possible to collect NPA samples before seroconversion. Viral RNA was detected in 3 of these samples, indicating that this assay can detect the virus even at the early onset of infection.

To further validate the specificity of this assay, NPA samples from healthy individuals (n=11) and patients suffered from adenovirus (n=11), respiratory syncytial virus (n=11), human metapneumovirus (n=11), influenza A virus (n=13) or influenza B virus (n=1) infection were recruited as negative controls. All of these samples, except one, were negative in the assay. The false positive case was negative in a subsequent test. Taken together, including the initial false positive case, the real-time quantitative PCR assay has sensitivity of 79% and specificity of 98%.

Epidemiological data suggest that droplet transmission is one of the major route of transmission of this virus. The detection of live virus and the detection of high copies of viral sequence from NPA samples in the current study clearly support that cough and sneeze droplets from SARS patients might be the major source of this infectious agent. Interestingly, 2 out of 4 available stool samples form the SARA patients in this study were positive in the assay (data not shown). The detection of the virus in feces suggests that there might be other routes of transmission. It is relevant to note that a number of animal coronaviruses are spread via the feco-oral route (McIntosh K., 1974, Coronavirus: a comparative review. *Current Top Microbial Immunol.* 63: 85-112). However, further studies are required to test whether the virus in feces is infectious or not.

Currently, apart form this hSARS virus, there are two known serogroups of human coronaviruses (229E and OC43) (Hruskova J. et al., 1990, Antibodies to human coronaviruses 229E and OC43 in the population of C.R., *Acta Virol.* 34:346-52). The primer set used in the present assay does not have homology to the strain 229E. Due to the lack of available corresponding OC43 sequence in the Genebank, it is not known whether these primers would cross-react with this strain. However, sequence analyses of available sequences in other regions of OC43 polymerase gene indicate that the novel human virus associated with SARS is genetically distinct from OC43. Furthermore, the primers used in this study do not have homology to any of sequences from known coronaviruses. Thus, it is very unlikely that these primers would cross-react with the strain OC43.

Apart from the novel pathogen, metapneumovirus was reported to be identified in some of SARS patients (Center for
Disease Control and Prevention, 2003, *Morbidity and Mortality Weekly Report* 52: 269-272). No evidence of metapneumovirus infection was detected in any of the patients in this study (data not shown), suggesting that the novel hSARS virus of the invention is the key player in the pathogenesis of SARS.

**Immunofluorescent Antibody Detection:**

Thirty-five of the 50 most recent serum samples from patients with SARS had evidence of antibodies to the hSARS (see FIG. 3). Of 27 patients from whom paired acute and convalescent sera were available, all were seroconverted or had 4-fold increase in antibody titer to the virus. Pairwise pairs of sera from additional SARS patients from clusters outside this study group were also tested to provide a wider sampling of SARS patients in the community and all of them were seroconverted. None of 80 sera from patients with respiratory or other diseases as well as none of 200 normal blood donors had detectable antibody.

When either seropositivity to HP-CV in a single serum or viral RNA detection in the NPA or stool are considered evidence of infection with the hSARS, 45 of the 50 patients had evidence of infection. Of the 5 patients without any virological evidence of Coronavirideae viral infection, only one of these patients had their sera tested >14 days after onset of clinical disease.

**Discussion**

The outbreak of SARS is unusual in a number of aspects, in particular, in the appearance of clusters of patients with pneumonia in health care workers and family contacts. In this series of patients with SARS, investigations for conventional pathogens of atypical pneumonia proved negative. However, a virus that belongs to the family Coronaviridae was isolated from the lung biopsy and nasopharyngeal aspirate obtained from two SARS patients, respectively. Phylogenetically, the virus was not closely related to any known human or animal *coronavirus* or *torovirus*. The present analysis is based on a 646 bp fragment (SEQ ID NO:1) of the polymerase gene, which indicates that the virus relates to antigenic group 2 of the coronaviruses along with murine hepatitis virus and bovine *coronavirus*. However, viruses of the Coronaviridae can undergo heterologous recombination within the virus family and genetic analysis of other parts of the genome needs to be carried out before the nature of this new virus is more conclusively defined (Holmes K V Coronaviruses. Eds Knipe D M, Howley P M Fields Virology, 4th Edition, Lippincott Williams & Wilkins, Philadelphia, 1187-1203). The biological, genetic and clinical data, taken together, indicate that the new virus is not one of the two known human coronaviruses.

The majority (90%) of patients with clinically defined SARS had either serological or RT-PCR evidence of infection by this virus. In contrast, neither antibody nor viral RNA was detectable in healthy controls. All 27 patients from whom acute and convalescent sera were available demonstrated rising antibody titers to hSARS virus, strengthening the contention that a recent infection with this virus is a necessary factor in the evolution of SARS. In addition, all five pairs of acute and convalescent sera tested from patients from other hospitals in Hong Kong also showed serumconversion to the virus. The five patients who has not shown serological or virological evidence of hSARS virus infection, need to have later convalescent sera tested to define if they are also seroconverted. However, the concordance of the hSARS virus with the clinical definition of SARS appears remarkable, given that clinical case definitions are never perfect.

No evidence of HMPV infection, either by RT-PCR or rising antibody titer against HMPV, was detected in any of these patients. No other pathogen was consistently detected in our group of patients with SARS. It is therefore highly likely that this hSARS virus is either the cause of SARS or a necessary pre-requisite for disease progression. Whether or not other microbial or other co-factors play a role in progression of the disease remains to be investigated.


We describe for the first time the clinical presentation and complications of SARS. Less than 25% of patients with coronavirus pneumonia had upper respiratory tract symptoms. As expected in atypical pneumonia, both respiratory symptoms and positive auscultatory findings were very disproportional to the chest radiographic findings. Gastrointestinal symptoms were present in 10%. It is relevant that the virus RNA is detected in feces of some patients and that coronaviruses have been associated with diarrhea in animals and humans (Caul E O, Egglestone S l. Further studies on human enteric coronaviruses *Arch. Viral.* 1977; 54: 107-17). The high incidence of deranged liver function test, leukopenia, significant lymphopenia, thrombocytopenia and subsequent evolution into adult respiratory distress syndrome suggests a severe systemic inflammatory damage induced by this hSARS virus. Thus immuno-modulation by steroid may be important to complement the antiviral therapy by ribavirin. In this regard, it is pertinent that severe human disease associated with the avian influenza subtype H5N1, another virus that recently crossed from animals to humans, has also been postulated to have an immune-pathological component (Chen C Y, Poon L J M, Lau A S Y et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease. *Lancet* 2002; 360: 1831-1837). In common with H5N1 disease, patients with severe SARS are adults, are significantly more lymphopenic and have parameters of organ dysfunction beyond the respiratory tract (Table 4) (Yuen K Y, Chan P K S, Peiris J S M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1
virus. *Lancet* 1998; 351: 467-471). It is important to note that a window of opportunity of around 8 days exists from the onset of symptoms to respiratory failure. Severe complicated cases are strongly associated with both underlying disease and delayed use of ribavirin and steroid therapy. Following our clinical experience in the initial cases, this combination therapy was started very early in subsequent cases which were largely uncomplicated cases at the time of admission. The overall mortality at the time of writing is only 2% with this treatment regimen. There were still 8 out of 19 complicated cases who had not shown significant response. It is not possible to a detailed analysis of the therapeutic response to this combination regimen due to the heterogeneous dosing and time of initiation of therapy.

Other factors associated with severe disease is acquisition of the disease through household contact which may be attributed to a higher dose or duration of viral exposure and the presence of underlying diseases.

The clinical description reported here pertains largely to the more severe cases admitted to hospital. We presently have no data on the full clinical spectrum of the emerging Coronavirus infection in the community or in an out-patient setting. The availability of diagnostic tests as described here will help address these questions. In addition, it will allow questions pertaining to the period of virus shedding (and communicability) during convalescence, the presence of virus in other body fluids and excreta and the presence of virus shedding during the incubation period, to be addressed.

The epidemiological data at present appears to indicate that the virus is spread by droplets or by direct and indirect contact although airborne spread cannot be ruled out in some instances. The finding of infectious virus in the respiratory tract supports this contention. Preliminary evidence also suggests that the virus may be shed in the feces. However, it is important to note that detection of viral RNA does not prove that the virus is viable or transmissible. If viable virus is detectable in the feces, this would be a potentially additional route of transmission that needs to be considered. It is relevant to note that a number of animal coronaviruses are spread via the fecal-oral route (McIntosh K. Coronaviruses: a comparative review. *Current Top Microbiol Immunol.* 1974; 63: 85-112).

### 8. Market Potential

The hSARS virus can now be grown on a large scale, which allows the development of various diagnostic tests as described hereinabove as well as the development of vaccines and antiviral agents that are effective in preventing, ameliorating or treating SARS. Given the severity of the disease and its rapid global spread, it is highly likely that significant demands for diagnostic tests, therapies and vaccines to battle against the disease, will arise on a global scale. In addition, this virus contains genetic information which is extremely important and valuable for clinical and scientific research applications.

### 9. Equivalents

Those skilled in the art will recognize, or be able to ascertain many equivalents to the specific embodiments of the invention described herein using no more than routine experimentation. Such equivalents are intended to be encompassed by the following claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference.

Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

### SEQUENCE LISTING

The patent contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US07547512B2). An electronic copy of the “Sequence Listing” will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed:

1. A method for detecting the presence of a N-gene of the hSARS virus in a biological sample, said method comprising:
   (a) contacting the sample with a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:2475, 2476, 2480 and/or 2481; and
   (b) detecting whether the nucleic acid molecule binds to said N-gene in the sample.

2. A method for identifying a subject infected with the hSARS virus, said method comprising:
   (a) obtaining total RNA from a biological sample obtained from the subject
   (b) reverse transcribing the total RNA to obtain cDNA; and
   (c) subjecting the cDNA to real-time PCR assay using a set of primers consisting essentially of the nucleotide sequences of SEQ ID NO:2475 and 2476, respectively.

3. A method for identifying a subject infected with the hSARS virus, said method comprising:
   (a) obtaining total RNA from a biological sample obtained from the subject
   (b) reverse transcribing the total RNA to obtain cDNA; and
(c) subjecting the cDNA to real-time PCR assay using a set of primers, consisting essentially of the nucleotide sequences of SEQ ID NO:2480 and 2481, respectively.

4. A kit comprising in one or more containers one or more isolated nucleic acid molecules consisting essentially of the nucleotide sequence of SEQ ID NO:2475 and/or SEQ ID NO:2476.

5. A kit comprising in one or more containers one or more isolated nucleic acid molecules consisting essentially of the nucleotide sequence of SEQ ID NO:2480 and/or SEQ ID NO:2481.